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Bryozoans are colonial, filter feeding aquatic invertebrates known from the tropical to Polar Regions. 
Due to the sessile nature of bryozoans and lack of immune system, they have evolved the ability to 
produce secondary metabolites as a chemical defense, which is enabling them to protect themselves 
from predators and to compete for space and food in a competitive environment and adapt to extreme 
environment conditions. Secondary metabolites are characterized by high chemical diversity. The 
chemical diversity of marine bryozoans is under-investigated and identification of new chemical 
compounds from marine bryozoans are still limited. Nearly 250 compounds have been recorded until to 
date. The present study was focused on isolation and characterization of new compounds from Arctic 
marine bryozoans. The novel compounds were isolated by using two different approaches.  
For bioassay-guided isolation, fractions of an extract of the Arctic bryozoan Securiflustra securifrons 
were screened for anticancer activity. The active fractions were analyzed by ultra-performance liquid 
chromatography high-resolution mass spectrometry (UPLC-HR-MS), and the elemental composition of 
the target compound was determined and dereplicated. The target compound was isolated from the 
aqueous extract of S. securifrons through mass-guided fractionation. The structure of the isolated 
compound, securidine A, was elucidated by 1D and 2D NMR spectroscopic techniques. Securidine A is 
a new β-phenylethylamine alkaloid. Securidine A was evaluated for its anticancer activity, and it did 
not show any significant cytotoxic effect. Furthermore, securidine A was tested in various bioassays 
including antibacterial, antidiabetic and the ability to inhibit the biofilm formation, but no bioactivity 
was observed.  
Fractions of the organic extract of S. securifrons were also screened for antibacterial activity. The 
chemical analysis of the active fraction revealed that it contained several securamines along with 
securidine A. The securamines and their anticancer activity were reported earlier by our research group. 
The pure compounds securamines C, E, H, I and J were tested against G + and G - pathogenic bacteria 
and yeast strains, and their ability to inhibit biofilm formation was also studied. Among these, 
securamine H was active against B. subtilis and the mode of action studies revealed that securamine H 
reduced the metabolic activity of B. subtilis but no interference with bacterial intracellular metabolic 
processes were found. To address any synergistic interactions, the minor compound securamine H and 
the major compound securidine A were assayed together, but no such effect was observed. 
A new secondary metabolite, dendrobeaniamine A was isolated from the Arctic bryozoan Dendrobeania 
murrayana through chemistry-guided isolation. A chemical analysis of the organic crude extract of D. 
murryana by using UPLC-HRMS with positive electrospray mode (ESI+) led to the isolation of lipo-
amino acid molecule, dendrobeaniamine A. The protonated elemental composition of the target 




spectroscopic methods.  The isolated compound was an acyl amino acid, which consist of a C12 fatty 
acid chain conjugated with the amino acid arginine. The bioactivity of dendrobeaniamine A was 
evaluated using cellular and biochemical assays, such as antimicrobial, anti-inflammatory and 
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1.1. Natural products 
Natural products have long been a source of drug molecules in the treatment of diseases in humans, and 
natural products continue to provide structurally unique bioactive lead molecules for the development 
of new drugs [1, 2]. To date, over 60% of all approved drugs originate from natural products or are 
designed on the basis of natural product structures [3]. Natural products can be isolated from both 
terrestrial and marine environments. Approximately 250,000 new natural products have been described 
and many of them are used either as drugs or served as lead compounds [4]. 
Natural products (NPs) are small organic molecules, biosynthesized by living organisms such as plants, 
animals and microorganisms. NPs are often referred to as primary and secondary metabolites, in which 
primary metabolites are directly involved in the growth, development and reproduction of the producer 
organism and they are essential for the survival of the producer organism [5]. In contrast, secondary 
metabolites are not necessary for the fundamentals of life, but they increase chances of long-term 
survival and successful reproduction [6, 7]. The distribution of secondary metabolites may be limited 
and occurring only in some specific group or species. The chemical composition and abundance of 
secondary metabolites are differ largely between organisms and geographic areas [8]. Secondary 
metabolites may have a broad range of extrinsic functions in order to improve the survival of the 
organism in a competitive environment with complex predator interaction, competition for space and 
nutrients, prevention of biofouling and adoption to extreme environmental conditions [9]. Secondary 
metabolites can also act as social signaling molecules (pheromones and siderophores) for interspecies 
communication, mating, to attract or activate symbiotic organisms, for hunting (venom and toxins) and 
quorum sensing [5-7]. The functions of some secondary metabolites are known whereas, others are still 
under investigation. A comprehensive statistical data analysis indicated that nearly 15,000 marine 
secondary metabolites were discovered in the period of 1985-2012 and only 4196 secondary metabolites 
were considered as bioactive based on available bioassays [10]. It has been proven that, many secondary 
metabolites from plants, animals and microorganisms possess a wide range of biological activities such 
as antibacterial, antifungal, antiparasitic, antifouling, antiviral and antitumor activities, and a great 
variety of molecular structures, which can be potential for drug development and other biotechnological 
applications in the food and cosmetic industries [11-14]. 
The biosynthesis of secondary metabolites can be complex and is carried out through intermediates or 
end products of primary metabolic pathways. Many of the secondary metabolites including polyketides, 
peptides, alkaloids, terpenes, steroids and shikimic acid derivatives are derived from the intermediates 
such as Acetyl coenzyme A (acetyl-CoA), shikimic acid, mevalonic acid and methylerythritol phosphate 




novel secondary metabolites are infinite due to the ways these intermediates can be combined and 
modified. In addition, the biosynthetic enzymes such as polyketide syntheses, non-ribosomal peptide 
synthases and fatty acid synthases are also involved in the biosynthesis of unusual secondary metabolites 
[7, 16]. The biosynthetic pathway of a secondary metabolite may be activated as a response to 
environmental changes, such as presence or absence of nutrients, changes in pH or pressure and presence 
of pathogens or predators [17] .  
 
Figure 1: The four major building blocks of secondary metabolites 
1.1.1. Structural diversity in natural products 
Natural products are characterized by their structural diversity [18]. They are represented by molecules 
and that are spanning from the simplest (e.g: aspirin) to complex structures (e.g: paclitaxel) [19] (Fig 
2). NPs occupy a wide range of chemical space, in the sense that, NPs tend have a higher number of 
chiral centers, higher number of hydrogen bond donors and acceptors, lower number of heavy atoms, 
lower molecular mass, higher diversity of ring systems and high polarity, which are not represented by 
synthetic compounds [20]. In addition, NPs tend to express more functional groups such as nitrogen-, 
sulphur- and halogen-containing groups, and a significantly higher number of oxygen atoms than 
synthetic compounds [21]. Moreover, the structures of NPs or secondary metabolites have evolved 
through biosynthesis by nature and are interacting efficiently with a wide variety of proteins. Therefore, 













1.1.2. Natural product derivatives 
Natural products often possess complex chemical structures and high biological activity compared with 
synthetic compounds. However, in order to improve the physio-chemical properties and reducing the 
complexity of the structure into simpler compound, NPs are chemically modified. The modifications are 
based on improving solubility and chemical stability, enhancing the bioactivity and selectivity, and 
modulating their drug ability with regard to absorption, distribution, metabolism, excretion and toxicity 
(ADMET). Such compounds are known as naturally derived compounds or natural product derivatives 
[18]. For example, an anticancer drug – paclitaxel, Taxol (Fig 3), isolated from the bark of the tree Taxus 
brevifolia, was modified chemically into a simpler structure to improve the efficacy and safety [23]. A 
complex marine natural product is halichondrin B (Fig 3), isolated from the marine sponges 
Halichondria okadai and Lissodendoryx sp. Halichondrin B is structurally complex, and it is a polyether 
macrolide (MW 1111.31) with in vivo and in vitro antitumor activity. Halichondrin B was totally 
synthesized for obtaining a sufficient amount and the structures of analogs were simplified [24, 25]. One 
of the analogs, eribulin mesylate (E7389) was a simplified ketone analog. E7389 showed the better 
activity than the parent compound due to the stability of the lactone in the single macrocyclic ring that 
is located on a right side of the parent molecule [26]. Eribulin mesylate (Halaven®) is currently in use 
for treating metastatic breast cancer [27]. In some cases, natural products are totally synthesized for 
economic reasons, environmental factors, and policy concerns. The yield of halichondrin B was very 
low and 12.5 mg of pure compound was obtained from 600 kg of sponges. Therefore, halichondrin B 
was totally synthesized [28]. 
Figure 3: Chemical structure of anticancer drugs, paclitaxel (Taxol) and marine derived natural product, 
halichondrin B. A part of a molecule, halichondrin B was modified (marked in red color) to replace an oxygen 
atom of the lactone linkage with a methylene group, and to introduce an amino group at the terminal of the side 
chain (marked in black color with red numbers in the structure of eribulin mesylate), in order to improve the 
efficiency of the compound. 
1.2. History of natural products from terrestrial to marine environment 
Historically, NPs have been derived from terrestrial plants to cure many human diseases. The medicinal 
use of plant derived natural products has been found in different cultures in history and is documented 
extensively [29]. The earliest medical document originates from the ancient Mesopotamia and, the well-




extracts from plants that were useful for the treatment of common cold, infections and inflammation 
[30]. The ancient Greek and the Roman physicians described the dosage and efficacy of plant-derived 
NPs, since some of the mixtures of herbal extracts contained harmful chemical substances [29]. Also in 
Asia, especially in the most primitive Chinese medicinal book Prescriptions for Fifty-Two Diseases, 
combinatorial drug formulae along with efficacies and synergies of natural medicines from plant extracts 
were described [31]. Until the eighteenth century, bioactive crude extracts or semi purified plant extracts 
were directly administered to humans for medical purposes [22]. In the early nineteenth century, a new 
era of medicine begun with the structural chemistry of pure compounds from crude extracts and 
administration of purified compounds in precise dosages [32]. In 1805, morphine (an analgesic agent) 
was isolated from the opium poppies of Papaver somniferum by Friedrich Sertürner, and this was the 
first alkaloid drug ever reported from the plant. In 1826, morphine was developed and commercialized 
by Emanuel Merck and considered as the first pure natural product. Further investigations of natural 
products in plant extracts led to the isolation and structure elucidation of several pure compounds that 
are still used for treatment of illnesses and diseases [33, 34]. Other well-known natural products are 
acetylsalicylic acid (aspirin) – an anti-inflammatory agent, isolated from willow bark, quinine and 
artemisinin – antimalarial agents, isolated from the bark of Cinchona tree and the leaves of the Artemisia 
annua plant respectively [29, 35, 36]. 
One of the most significant medical discoveries in the twentieth century was the first antibiotic penicillin 
G derived from the terrestrial fungi Penicillium notatum by Alexander Fleming in 1929 [37, 38]. This 
discovery eventually led to an extensive screening of microbes, particularly soil actinomycetes and 
fungi, resulting in several antibiotic compounds and immunosuppressant agents including tetracycline 
(Streptomyces species) and cephalosporin C (Cephalosporium acremonium), rapamycin (Streptomyces 
species) cyclosporine A (Trichoderma species) [39]. In addition, a cholesterol lowering agent, 
mevastatin and an anti-parasitic drug, ivermectin were also isolated from Penicillium, Streptomyces and 
Aspergillus species, respectively [40, 41]. Plants sources were also examined to identify anticancer 
drugs by the United States of America National Cancer Institute (NCI) during the 1970s, resulting in 
the discovery of the anticancer drugs taxol, camptothecin analogs from the bark of tree (Camptotheca 
acuminata) and the vinca alkaloid vincristine from the Madagascar periwinkle, Catharanthus roseus [2, 
23, 42]. A study on the sources of drugs between 1981 to 2010 showed that nearly half of the new drugs 
(49%) were naturally derived compounds either semi-synthetic analogues of natural product or synthetic 
compounds based on natural-product pharmacophores. Many of them were antimicrobial agents 
(antibacterial, antiviral and anti-parasitic drugs) [20, 43, 44]. 
The Oceans cover almost three quarters of the Earth’s surface, and they represent an abundant amount 
of biological diversity (census of marine life, 2000-2010) [45]. However, the number of traditional 




in medicinal applications were systematically described first by the Roman philosopher Plinius noted 
that, sponges with pure wine were used for the treatment of heart aches as well as all kinds of wounds, 
bone fractures, dropsy, stomach aches and infectious diseases [46]. In the fortieth century, a variety of 
iodine rich seaweed was used to treat low incidence of goiter in China and Japan. The red seaweeds 
Chondrus crispus and Mastocarpus stellatus were used for treating cough and cold, sore throat and 
bronchitis for several centuries in Ireland. In the 1940s, the first antibiotic cephalosporin C was isolated 
from the marine fungus Acremonium chrysogenum and characterized in 1961. The cephalosporin C was 
used as a lead for the development of the antibiotic class of cephalosporins and marketed as cephalothin 
in 1964 [47]. A significant marine natural product discovery was the identification of the unusual 
nucleosides spongothymidine and spongouridine (Fig 4), which contained arabinose sugar. Both were 
obtained from the Caribbean sponge Tethya crypta by Bergmann and Feeney in 1951 [27]. These two 
compounds served as lead structures and eventually led to the development of the anticancer drug 
cytarabine (cytosine arabinoside - Ara-C) and the antiviral drug vidarabine (9-β-D- arabino furanosyl     
adenine - Ara-A). They are still in use today to treat acute myelocytic leukemia and non-Hodgkin’s 
lymphoma and Herpes simplex infections respectively [28]. This discovery eventually led to the research 
in marine natural products chemistry and inspired researchers to search for drugs from marine 
organisms.  
The systematic investigation of marine organisms for novel biologically active compounds begun in the 
late 1970s and revealed that many bioactive compounds were novel with unique chemical structure 
which have not been seen in terrestrial sources [48]. In the beginning, the collection of marine organisms 
was made primarily by skin diving and the samples were obtained from seashores and shallow waters. 
The development of reliable scuba diving, modern snorkeling techniques and the use of remotely 
operated vessels (ROVs) provided to access a wide range marine habitats and organisms, resulting in 
the characterization of nearly 10,000 marine natural products [2, 20, 49]. From 1990-2003, the number 
of MNPs increased to more than 14,800 according to the Marinlit database and more than 1000 MNPs 
have been reported each year since 2008 [27]. More than 50,000 molecules are to date reported in the 
Dictionary of Marine Natural Products [50]. In comparison with 200,000 terrestrial NPs, the number of 









Figure 4: Chemical structures of the marine natural products spongouridine (R=H) and spongothymidine (R=Me) 




1.3. NPs drugs - Challenges and prospects 
In the 1990s, the research on natural products significantly decreased, because natural products drug 
development in pharmaceutical companies was a time consuming and tedious process including 
identification and purification of NPs and the modification of complex molecular structure of NPs, 
which are often challenging to synthesis [44, 51]. Particularly, a high rate of rediscovery of known 
compounds was one of the major factors leading to the decreased interest from natural products 
pharmaceutical companies and academic research groups [52]. In addition, the complex mixture of crude 
extracts of NPs was not effectively detected by automated high-throughput bioassay screening, due to 
their solubility and low concentration of minor active metabolites masked by major metabolites in crude 
extracts [53]. Moreover, low abundance of pure compounds (10-5 to 10-7 wet weight basis) from natural 
sources were not sufficient to analyze chemical and biological properties [54]. For example, a potent 
anticancer agent, dolastatin 10 was isolated from a sea hare, Dolabella auricularia and nearly two tons 
of D. auricularia was required to produce the first milligram of dolastatin 10, for testing its biological 
activity. This seasonal collection of sea hare from the island of Mauritius in the Indian Ocean took over 
ten years [28]. Meanwhile, the introduction of combinatorial chemistry along with high throughput 
screening (HTS) were mainly engaged on the drug development process instead of focusing on natural 
product research [44]. HTS allows for bioactivity screening of large number of small molecule 
compounds, which are chemically synthesized by combinatorial chemistry. Both bioactivity screening 
and synthesis of compounds can be done in short periods of time [44]. However, the chemical diversity 
in small molecule synthetic libraries developed by combinatorial chemistry was low, since the high 
number of compounds were produced from limited set of chemical scaffolds and these technologies 
delivered relatively few approved novel or new chemical compounds compared to NPs and their 
derivatives [55] (Fig 5 and 6).  
A comparative analysis between the chemical diversity between NPs, marketed drugs and small 
molecule synthetic libraries revealed that, 40% of the studied NPs structures were not represented from 
the synthetic libraries [56]. Another comparative analysis of approved new chemical entities between 
1981-2010 indicated that, the chemical diversity in NPs is higher than synthetic small molecule libraries 
due to the wide range of structural and physiochemical properties including larger molecular size, 
greater three-dimensional complexity, lower hydrophobicity and increased polarity and fewer aromatic 
rings [20, 57]. In addition, molecular complexity in NPs is one of the important features that differentiate 
them from synthetic compounds. Synthetic compounds are commonly flat and rigid molecules, whereas 
natural products generally contain more complex scaffolds, which is important in drug design. The 
structural complexity in NPs has been correlated for their biological activity and ability to interact with 
specific receptor sites on or within cells [58, 59]. Many NPs have also evolved to utilize transmembrane 











Development of new methods in bioactivity screening and advances in analytical techniques are 
currently in use to address the challenges of natural products drug discovery. One of the approaches is 
dereplication, which refers to the rapid detection of known compound at the earliest stage of natural 
product drug discovery. Over 246,000 compounds have been reported from the nature, with 
approximately 4000 new compounds being added each year [61]. Dereplication strategies are the ability 
to match molecular features (spectroscopic data) of unknown NPs to the stored spectroscopic data in the 
commercial databases and it is implemented after initial screening of extracts or semi-purified extracts 
[62]. The dereplication process generally involves a combination of various advanced analytical 
methods also known as hyphenated techniques such as LC-MS, (U)HPLC-HRMS, HPLC-PDA-NMR, 
and these techniques often facilitate the search for known compounds through natural products 
commercial databases including, The Dictionary of Marine Natural Products, ChemSpider, SciFinder 
Scholar, AntiMarin and MarinLit [63]. 
Bioactivity guided isolation: The compound isolation from crude extracts has been prioritized based 
on the observed biological activity. In this method, the crude extract and fractions are tested for their 
potential biological activity in in-vitro bioassays such as biochemical and cell-based assays, before the 
isolation of target bioactive substances [64]. This type of bioactivity screening is often linked with HPLC 
fractionation, and after each fractionation step, the fractions are tested for bioactivity. When the 
chemical complexity of the fractions is reduced to a limited number of compounds, the fractions are 





















Natural products (NPs) and their derivatives
synthetic compounds
Figure 5: Approved NPs drugs and completely 
synthetic drugs represent equal share in the late 
1980s and 2000. The trend of approved NPs 
drugs was increased in 2001-2005.  In 2006-
2010, it was relatively lesser NPs than synthetic 
molecules, which is correlating with the 
decommissioning of many natural product 
discovery programs in the pharmaceutical 
industry [20, 44]. 
Figure 6: Approved drugs between 1981-2010. 
The approved drugs based on natural product 
(NP), natural product-derivatives (ND), and 
synthetic compound based on natural product 




as dereplication [65]. Bioassay guided fractionation is a tedious and time-consuming process, it requires 
significant amounts of crude extract and multiple fractionation steps, but automated fractionation in 
combination with high throughput screening can be cost effective. It is very important that the 
dereplication is efficient in order to avoid re-isolation and chemical characterization of previously 
reported bioactive compounds [66]. In some cases, the crude extract may have an activity that is lost 
after fractionation due to synergistic interaction between multiple compounds, in fact the synergy might 
account for better activity of mixtures than isolated compounds [67]. Therefore, a more efficient 
approach is necessary to overcome this limitation.  
Chemical guided isolation: The main aim of this approach is to discover new NPs or NPs with 
novel chemical structures through the dereplication process. In this method, the molecular features of a 
target compound (unknown) is directly identified in crude extracts prior to detecting biological activity. 
The combination of LC (UHPLC) with UV diode array and HRMS allows detecting minor compounds 
present at low concentration (µg to ng) in crude extract without prior isolation. More importantly, it 
provides structural information of the targeted compounds including the molecular weight with high 
mass accuracy and the measurement of isotopic pattern that is used for calculating elemental 
compositions (molecular formula). The advantage of chemical guided isolation is, to identify new 
compounds directly in extracts prior to bioassay and purification. It requires small (microgram) 
quantities of sample material [66, 68]. However, the isolated new chemical compounds from crude 
extracts may not be bioactive. 
Advances in microbial genomics, in particular, genome sequencing or genome scanning provides an 
efficient way for the discovery new natural products biosynthetic gene clusters. For example, the whole 
genome sequencing of actinomycetes revealed that they possess 20 gene clusters, responsible for 
biosynthesis of different classes of secondary metabolites including polyketide synthase (PKS) and non-
polyketide ribosomal synthase (NRPS) [69]. Another alternative approach is metagenomics that can also 
be used to discover new natural products from uncultivable marine microorganisms such as bacteria (< 
1% known) and fungi (<5% known), that are potential producers of new secondary metabolites [51]. 
The biosynthetic genes (PKS) for the byrostatin family of antitumor compounds were identified in 
uncultivated symbiotic bacterium, Candidatus Endobugula sertula using a metagenomics approach [70]. 
Accessing unexplored habitats (Polar Regions and deep sea) and restricted group of micro and 
macroorganisms such as psychrophiles, thermophiles and acidophiles, can also provide novel 
compounds with unusual chemical structures [71]. 
1.4. Marine environment and biodiversity 
The oceans cover more than 70% of the Earth’s surface area and are the richest biosphere, containing 




counterparts [45]. Of the 33 animal phyla reported to date, 32 are represented in the aquatic environment, 
and 15 of them are exclusively found in the oceans [72]. In addition, marine microorganisms are major 
constituents of the marine ecosystem and actively participate in biological processes. The microbial 
diversity in marine environment is enormous and it is estimated that sea water contains viruses at 
107pfu/ml, bacteria at 106 cfu/ml, fungi at 103 cfu/ml and microalgae at 103 cell/ml and marine sediments 
contain microorganism at 109 cfu/ml [73]. The abundancy of marine biodiversity provides a potential 
reservoir of bioactive natural products, which contains structurally diverse chemical compounds with 
unusual combinations of functional groups including halogenated compounds especially bromine and, 
chlorine and sulfated compounds that are not found in terrestrial organisms [74-76]. A large array of 
chemical diversity in marine secondary metabolites not only depends on biodiversity, it depends on 
geographical area as well. The marine organisms can be found from the tropical to polar waters and 
shallow to deep waters including benthic habitats and hydrothermal vents [77]. The living conditions of 
marine plants, animals and microbes are extremely different compare to terrestrial species with regard 
to environmental factors such as light, temperature, salinity, pressure, water current, dissolved oxygen 
content, pH and nutrient concentration [78-80]. These diverse habitats and properties might interfere or 
modify the biosynthetic pathways in marine organisms, resulting in the production of biologically active 
secondary metabolites such as terpenoids, alkaloids, polyketides, peptides, with a variety of unusual 
structures [81]. Moreover, marine organisms are catalyzing biochemical reactions with enzymes. 
Halophilic marine microbes possess many hydrolytic enzymes that are capable of functioning under 
conditions that lead to precipitation and denaturation of protein. A comparative analysis showed that 
natural products from marine species are superior to natural products from terrestrial in terms of 
chemical novelty. This study showed that 71% of the chemical scaffolds in the dictionary of marine 
natural products were exclusively found in marine organisms [58]. 
1.4.1. Natural products from marine invertebrates 
Marine natural products have primarily been isolated from the marine invertebrate phyla Porifera, 
Echinodermata, Mollusca, Cnidaria, Bryozoa and sub phylum of Chordata –Tunicata [77]. A statistical 
analysis of marine natural products data from 2000 to 2017 estimated that approximately 60% of MNPs 
are isolated from marine invertebrates alone (Fig 7), and that MNPs exhibited a higher rate of bioactivity 
compared to NPs derived from terrestrial organisms [82]. Many marine invertebrates are sessile and 
soft-bodied animals, which are thriving within complex ecosystems [83]. Due to their sessile nature and 
absence of complex immune system, these organisms have evolved to develop chemical defenses, also 
known as NPs, to better their chances of survival. This includes NPs that deter predators or paralyze the 
prey, inhibit pathogens and fouling organisms on their surface and protection from UV radiation [84, 
85]. The chemical defenses in marine invertebrates against predators has been proven in several studies 




snail, Conus magus. The conotoxins serve to immobilize the prey of the cone snail by targeting different 
voltage-gated ion channels (Na+ and K+). The conotoxin derivative MVIIA is currently used as an 
analgesic drug and it is the first analgesic drug from a marine source. This compound proved to be 1000 
times more active than morphine, which was derived from a terrestrial plant [32]. Many marine natural 
products isolated from marine invertebrates are extremely potent by means of bioactivity, probably 
because the compounds are rapidly diluted into the seawater. The potency of these compounds enables 
them to interact their biological target with high biochemical specificity [87]. These biologically active 
molecules have drug like properties, and they are capable of orally active due to relatively low 
lipophilicity. These bioactive natural products provide potential leads for pharmaceuticals (e.g. anti-












Figure 7: Total number of new compounds isolated from different marine sources over the last ten years  
1.4.2. Natural products from the symbionts of marine invertebrates  
Numerous MNPs isolated from marine invertebrates, are structurally similar to marine microbial 
secondary metabolites, suggesting that, the microorganisms are possibly involved in the biosynthesis of 
the natural products [90, 91]. Marine invertebrates live in close association with microorganisms such 
as bacteria, fungi and cyanobacteria, which can be symbiotic or merely commensal or mutualistic [92]. 
The abundance of microbial diversity and the number of microbes in marine invertebrates may exceed 
than in seawater. In cnidarians for instance, the mucus of corals may contain 100-1000 times more 
microorganisms than the surrounding seawater [93, 94]. The microbiome of marine invertebrates reside 
either on the surface (epibionts) or an internal space (holobionts) of their host, also known as 
endosymbionts and they may contribute up to 40-60% of biomass [95, 96]. The associated microbes are 
possibly the true producers of many ‘invertebrate metabolites’ or ‘invertebrate NPs [97].  
Microbial symbiosis with bacteria, archaea and unicellular eukaryotes (dinoflagellates) have been 











symbiosis is mainly based on small molecules, produced by microbes. These symbiotic microorganisms 
constantly involve within their animal host environment by exchanging nutritional molecules and 
molecules that can help the host to resist the pathogens and parasites, while others are quorum sensing 
molecules that establish its colonization within their host [95]. For example, the cyanobacterial 
symbiont, Prochloron didemni interacts with the host marine invertebrate ascidian, Lissoclinum patella 
for nutritional exchange. The cyanobacteria Prochloron spp. provide food by photosynthesis to their 
host and fixates the carbon, which is necessary for the host growth and in return, the cyanobacteria 
consume and recycle nitrogen from the host. These small molecules are possibly involved in the 
biosynthesis of defensive chemicals of their host [98]. The cytotoxic secondary metabolites patellamides 
were isolated from the marine invertebrate, ascidian L. patella [99]. However, the compound 
patellamide is possibly produced by one of the Prochloron species, P. didemni. A genome sequence 
analysis of the symbionts of ascidians revealed that Prochloron spp. synthesize patellamides by a 
ribosomal pathway [98, 100].  
The marine natural product okadaic acid is a polycyclic polyether and it is a selective inhibitor of 
serine/threonine protein phosphatases. Okadaic acid is used as a research tool, as it is a potent probe for 
studying various molecular, cellular and biochemical mechanisms of neurotoxicity (e.g: Alzheimer 
diseases) [101, 102]. Okadaic acid was originally isolated from the marine sponges, Halichondria 
okadai and H. melanodocia. However, it was later shown to be produced by the sponge-associated 
dinoflagellates Prorocentrum sp. and Dinophysis sp. [103-106]. Okadaic acid is a polyketide and the 
structure is closely related to another shellfish toxin, brevetoxin, which is produced by the dinoflagellate, 
Karenia brevis [78].  
Another example of the microbial origin of a MNP is the antitumor agent, dolastatin 10, originally 
isolated from the marine mollusk Dolabella auricularia. A synthetic truncated analogue of dolastatin 
10, monomethyl auristatin E, is currently used as a part of the antibody conjugated drug marketed as 
Adcetris [27]. Dolastatin 10 was later found to be a cyanobacterial metabolite, produced by a Symploca 
sp. (strain no. VP642), and that the cyanobacterium is a dietary source of D. auricularia [107, 108]. A 
close examination of the structural features of the cytotoxic compound Ecteiascidin   ̶  743 (ET-743), 
isolated from the tunicate Ecteinascidia turbinate, reveals that this compound bears a close resemblance 
to the antibiotic compound safracin B produced by Pseudomonas fluorescens, suggesting that ET-743 
might be of bacterial origin [109]. This was confirmed by a metagenomics study where, the complete 
genome of the ET-743 producer is the gammabacterium Candidatus Endoecteinascidia frumentensis (E. 
frumentensis) [110, 111]. Candidatus E. frumentensis is an endosymbiont of the tunicate E.turbinate 
and it is likely a species-specific endosymbiont, since this compound is not identified in any other marine 





 Figure 8: Marine natural products biosynthesized by microbial symbionts, isolated from marine invertebrates. 
1.5. FDA and EMA approved marine derived drugs 
There are currently nine marine derived drugs approved by the Food and Drug Administration (FDA) 
and the European Medicines Agency (EMA), 21 are in clinical trial phase III, and many more are in 
clinical trial phase I and II. The approved drugs are represented almost each of the marine chemical 
classes such as alkaloid, peptide, polyketide and polysaccharide. Chemical structures of approved drugs 
can be seen in Fig 9.  
Cytarabine and vidarabine were the first marine derived drugs and, both are synthetic pyrimidine and 
purine nucleoside derivatives of spongothyminide and spongouridine, which were isolated from the 
Caribbean sponge Tethya crypta. Cytarabine (trade name Cytosar-U) can be chemically synthesized or 
produced by heterologous expression by the bacterium Streptomyces griseus. It was approved by the 
FDA in 1969 for the treatment of non-Hodgkin’s lymphoma, myeloid and myelocytic leukaemia, and is 
still being in clinical use. Vidarabine (Vira) was approved by FDA in 1976 as an antiviral drug against 
Herpes viruses and poxviruses. However, the viral strains developed resistance to vidarabine, and it was 
discontinued as an antiviral drug.  Presently, vidarabine is only used for ophthalmologic applications 
[28]. Ziconotide was the first marine derived analgesic agent for the treatment of severe chronic pain 
associated with cancer and spinal cord injury.  It selectively targets N-type voltage- sensitive calcium 
channels, inhibiting the activity of a subset of neurons including pain-sensing primary nociceptors. 
Ziconotide is the synthetic form of ω-conotoxin peptide MVIIA, which is a peptide composed of 25 
amino acid residues with three sulfide bonds. Ziconotide was approved by the FDA in 2004 and by the 




snail Conus magus in 1982 and was synthesized in 1987. Ziconitide is an unmodified marine natural 
product [113].  
The second anticancer drug, Ecteinascidin-743 or trabectedin, is a tetrahydroisoquinoline alkaloid, 
containing three fused tetrahydroisoquinoline rings, eight rings including one 10-membered heterocyclic 
ring containing a cysteine residue and seven chiral centers. ET-743 was produced by semi-synthesis 
from the antimicrobial product cyanosafracin B, which was obtained by fermentation of the bacteria 
Pseudomonas fluorescens, to overcome the supply issue of ectinascidine 743. ET-743 is also known as 
Yondelis and was approved by EMEA in 2007 for treatment of refractory advanced soft-tissue sarcomas 
and subsequently in 2009 it was approved in the EU for the treatment of relapsed ovarian cancer. 
Trabectedin binds to the DNA minor groove causing DNA damage and interferes with the cell division 
and the gene transcription processes and DNA repair machinery [114].  
Another anticancer compound, eribulin mesylate, is a simplified ketone analogue of halichondrin B 
isolated from the marine sponges in 1987. The total synthesis was achieved in 1992 to solve the supply 
problem. The eribulin mesylate trade name is Halaven, and gained approval from FDA in 2010 and 
EMEA in 2011 for treating metastatic breast cancer. Eribulin mesylate inhibits the growth phase of 
microtubules, without affecting microtubule-shortening phase, and this leads to disruption of mitotic 
spindles and cell cycle arrest [24]. The antineoplastic drug, brentuximab vedotin is a derivative of the 
potent cytotoxic linear peptide dolastatin 10, which was isolated from the marine sea hare Dolabella 
auricularia in 1972. Dolastatin 10 can be produced by the cyanobacteria Symploca hydnoides (new 
name - Caldora penicillata) and the total synthesis was achieved in 1987. The synthetic form of 
dolastatin 10 is a monomethyl auristatin E (MMAE) analog that combined to tumor specific antibody 
anti-CD30 antibody, forming antibody-drug conjugates in order to improve efficiency and reduced 
cytotoxity. The antibody-drug conjugates, binds to tubulin in CD30 and tumor cells and disrupt the 
microtubule network.  Brentuximab vendotin was approved by FDA in 2011 for the treatment of 
relapsed and refractory Hodgkin’s lymphoma and anaplastic large cell lymphoma and is marketed as 
Adcetris [108].  
The trabectedin analog, lurbinectedin or Zepsyre, is a synthetically derived anticancer agent. 
Lurbinectedin has been granted orphan drug status in 2019 by EMEA for the treatment of small cell 
lung cancer [115]. The latest marine derived antiproliferative agent, Plitedepsin was approved by 
Australia Therapeutic Good Administration (ATGA) in January 2019 for the treatment of relapsed and 
refractory multiple myeloma in combination with the corticosteroid medication dexamethasone. 
Plitedepsin is a cyclic peptide isolated from a Mediterranean tunicate Aplidium albicans in 1991. It is a 
synthetic derivative of didemnin B and was synthesized in 2000. Plitedepsin binds a specific protein 
(eEF1A2), which is overexpressed in cancer cells and blocks its function, which leads to protein 




[115]. Lovaza is an antihyperlipidemic drug, which normalize and control the triglyceride level in the 
human blood, and it was approved in 2014 by FDA and EMA. Lovaza is produced through esterification 
of the natural fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Both EPA and 
DHA are polyunsaturated fatty acids (PUFAs), mainly extracted from fish. Both are used as omega-3 
dietary supplements and act as inhibitors of thrombocyte aggregation and protection of cognitive 
functions in aging. Lovaza inhibits the synthesis of triglycerides and increases peroximal beta-oxidation 
of fatty acids in the liver [116] (Fig 9).  
A final example of marine derived drugs is the Carragelose, derived from the Carrageenan. Carrageenan 
is a high molecular weight polysaccharide and it belongs to a family of linear sulfated polysaccharides. 
It is extracted from edible red seaweeds mainly Chondrus crispus and Rhodophyceae sp. Iota-
carrageenan is a sub group of carrageenan, marketed as Carragelose in 2014.  Carragelose is an antiviral 
nasal spray and it is proven to be a clinically effective treatment of early symptoms of common cold 
viral infections of the upper respiratory tract. Carragelose sold as an over-the counter (OTC) drug that 












Figure 9: Commercially available marine derived drugs  
1.6. Natural products research on marine bryozoans 
The majority of MNPs has been isolated from marine invertebrate phyla including Porifera, Cnidaria, 
Echinodermata and Mollusca. NPs research on the phylum Bryozoa is limited and the bryozoans are 
still an underexploited resource. Since 1986, all structurally elucidated and published MNPs have been 
annually reviewed in the journal Natural Product Reports as the series Marine Natural Products. Over 




marine sources such as invertebrates, phytoplankton, green, brown and red algae, diatoms, mangroves 
and other intertidal plants and microorganisms (Fig 10). Among the 9301 citations, only about 45 studies 
focused on marine bryozoans, and about 80 compounds were described. Over 8000 bryozoan species 
are known, and a total of approximately 250 new secondary metabolites have been isolated and 
characterized so far from about 50 species of marine bryozoans. In addition, about 100 studies have 














Figure 10:  Number of marine natural products derived from bryozoans for last ten years (2008 -2018). 
The reason for the limited number of studies on NPs research in marine bryozoans is possibly the 
taxonomic difficulties with the phylum that bryozoans might resemblance organisms belonging to other 
phyla such as anthozoa or endoprocata. In addition to that, bryozoans are often mistaken for marine 
plants or seaweeds [129]. The examination of large numbers of small colonies is not easy and it is 
laborious and time consuming. It is also difficult to obtain sufficient biomass for natural product research 
because many bryozoan have encrusted, erected and foliosed growth forms and the collection of larger 
quantities of biomass have permitted the isolation of small amount of secondary metabolites. For 
example, 13 tons of the marine bryozoan Bugula neritina (erected form of bryozoan) were harvested to 
yield only 18 g of pure bryostatin I, which was used for anticancer evaluation in phase I clinical trials 
[28, 130]. Accessibility of marine bryozoans might be another possible reason, since half of the marine 
bryozoans have habitats deeper than 40 m and about 30% of the species are found below 700 m in depth. 
In order to acquire species diversity of marine bryozoans, dredges or trawls must be engaged along with 
SCUBA diving and those operations are expensive [129, 131].  
The increase in discovery of new MNPs has significantly declined due to high rates of rediscovery of 

























because the emergence of drug resistance has serious implications for the prevention and treatment of 
diseases [133]. Therefore, searching for new chemical entities with novel structures from underexplored 
areas such as Arctic and Antarctic and underexplored biological sources are necessary. Thus, the 
discovery of new MNPs can potentially provide new and improved therapeutics for human illnesses, 
along with other innovative products for other industrial activities such as nutraceuticals and 
biotechnology applications [77]. 
Coldwater marine organism or psychrophiles are found in temperate and polar deep waters with 
temperatures ranging from -2 °C to + 4 °C. This includes the tropical deep-sea, where the temperature 
is nearly constant 4 oC as well as Antarctica, Canadian maritime, the Northern Sea of Japan and the 
North Sea 60 oN latitude [71]. Diverse and highly bioactive compounds have been isolated from the 
different sources of cold-water marine organisms including microbes and marine invertebrates such as 
sponges, cnidarians, tunicates and bryozoans. A marine bacterium, Bacillus sp., isolated from the sea 
mud near the Arctic pole, produces the new cyclic lipopeptides, mixirins A-C. These compounds 
displayed significant cytotoxicity against human colon tumor cell line (HCT-116) [134]. The brominated 
tryptophan derivatives, eusynstyelamides were isolated from the cold-water bryozoan, Tegella cf. 
spitzbergenesis. The eusynstyelamides exhibited antibacterial activity against Gram- positive (S. 
aureus) and Gram-negative (E. coli) bacteria [135]. 
1.6.1. Marine bryozoans 
Bryozoans are aquatic invertebrates, belong to a phylum Bryozoa, otherwise known as Ectoprocta or 
Polyzoa (colonies of many individuals). Until 1831, bryozoans were misclassified as corals or hydroids, 
because they all have a moss-like appearance and encrusting formations. Thus, bryozoans are commonly 
called as ‘moss animals’ or ‘sea mats’. The name ‘‘Bryozoa’’ was coined by Christian Gottfried 
Ehrenberg, he described the presence of separate mouth and anus openings in bryozoans which, 
distinguished them from those animals that lacked this complex feature (i.e ‘‘Anthozoa’’). In 1869, 
Hinrich Nitsche discovered another group of animals ‘Endoprocta’ that was similar to the phylum 
Bryozoa. Although both share a similar filter feeding mechanism, they possess a different internal 
anatomy. The position of the anus, either inside or outside the ring of tentacles (lophophore), is the main 
differentiating feature. However, the phylum Bryozoa is still widely referred to as Ectoprocta [136-138].  
Diversity: The phylum Bryozoa is divided into three classes based on the structure of the zooid 
exoskeletons and the colony organization. The three classes consists of four orders, 187 families and 
808 genera and currently more than 6000 species have been described as living forms [139]. The class 
Phylactolaemata contain exclusively freshwater bryozoans with non-calcified colonies and it contain the 
order Plumatellida with six families and about 90 representative species. The oldest class, Stenolaemata, 




whereas the three other are extinct. The order Cyclostomata is characterized by calcified exoskeleton 
colonies with cylindrical or tube shaped zooids. The largest class, Gymnolaemata, is predominately 
found in the marine environment. It contains two orders, Ctenostomata, which have gelatinous colonies 
rather than calcified body walls and approximately 320 representative species. The largest and most 
successful order is Cheilostomata, which is exclusively found in the marine environment. The colonies 
of cheilostome bryozoans are composed of box shaped zooid and reinforced with calcium carbonate 
exoskeleton. Cheilostomata consists of 4921 living species. To date, the number of fossil species of 
bryozoans are higher than that of existing species, and a total of 15,000 species have been recorded [137, 
140-142]. 
Habitat and abundance: Bryozoans are benthic, sessile colony forming invertebrates. These colonial 
invertebrates are predominantly found in the marine environment, and they are living from the intertidal 
zone down to the Deep Ocean. Bryozoans are widely distributed from polar to tropical waters, and they 
can also be found in fresh and brackish waters. The basal body portion of the bryozoan colony (Zoarium) 
is firmly attached to rocky substrates, seashells, coral reefs, hydroids, kelps, seaweeds. They are able to 
colonize artificial substrates such as pipes, boats or ship hulls, which is then referred to as biofouling.  
The bryozoan colonies develop in different forms, depending on the respective environment. The 
patterns or forms are branched, lobed, tuft, foliaceous, encrusting formation and appearing to be rigid 
or flexible. The colony size can vary from few millimeters to several decimeters. Large colonies of 
bryozoans may provide food, habitat and nursery ground for many micro and macro organisms, 
including bacteria, algae, diatoms, polychaets, hydroids, sponges, arthropods, larvae of other 
invertebrates and fishes [140, 143-147]. 
Basic body plan: Bryozoan colonies are composed of many tiny individuals or units called ‘zooids’. 
Thus, the phylum Bryozoa is also known as polyzoa. The zooids are genetically and morphologically 
identical and polymorphic in nature, and the size range is approximately 0.5 mm to 1mm in length. The 
growth of zooid size depends on the environmental factors such as temperature and salinity [144, 148]. 
The zooids are interconnected to the neighboring zooids through inter zooidal pores or communicating 
pore and each zooid is separated by body wall that secretes chintinous or gelatinous or calcified skeleton 
material (zoecium). The zooids in bryozoan colonies have two different types of zooids. The basic units 
of autozooids are responsible for feeding for the entire colony and heterozooids are polymorphic and 
non-feeding zooids. These zooids have different functions such as strengthening of the colony 
(kenozooids- the zooids are greatly reduced for attachment to substrate also act as space fillers), 
reproduction (ovicells or gonozooid – specialized for brooding the eggs), cleaning (vibracula – flagellar 
operculam) of detritus building up on the colony and protection against fouling such as bacteria and 
diatoms (varicularia – well developed opercula, defend the colony) from the predators and grazers [137, 




The cystid is the outer casing that is attached to the body wall and the body cavity largely occupied by 
a spacious coelom. The polypide comprises of protrusible lophophore, U-shaped digestive tract and 
other internal organs such as nerve system. The lophopores or tentacles have a coelomic space that 
connects with other tentacles to form a coelomic ring, which is located at the base of tentacle crown. U-
shaped digestive tract contains pharynx, a slender oseophagus, a stomach and a narrow intestine that 
passes to a short rectum that opens (mouth) and terminates (anus) near the ring of tentacles (lophophore). 
The nerve system, ganglion is located at the base of tentacles crown retractor muscles [136-138]. 
Bryozoans are suspension feeders and the autozooids collect food particles by using their ciliated 
tentacles to catch the prey, mainly diatoms and other phytoplankton from the surrounding seawater. 
Moreover, the bryozoan tentacles, or lophophores can be withdrawn inside of the body cavity for 
protection. Eversion of the withdrawn tentacles by retractor muscles is mainly controlled by the 
elevation of hydrostatic pressure of the body fluid. The nutrients are distributed to non-feeding zooids 
through mesothelial funiculus cords that are concentrated around the gut and extended to the 
communicating pore in the cystid body wall. Bryozoans are hermaphrodites with male and female zooids 

















Figure 11: The schematic image of generalized bryozoan morphology is shown as a group of autozooids and a 
polymorphic zooid, ovicell. The separate image of autozooid can be seen above with labelled body parts. 
Lophophore (retracted and extended) and digestive tract are shown in orange. Skeleton and muscle are shown in 
black. The funicular bodies connect the zooid, can be seen in black dotted strands. Ovary (bottom) and Ovicell 




Reproduction: The reproduction in bryozoans occurs, both sexually with dispersal of larvae and 
asexually by budding. The sexually mature zooids (gonozooids) produce eggs and spermatozoa. The 
embryos develop from fertilized eggs in the brooding chamber, and when mature, they are dispersed as 
free-feeding larvae ‘cyphonautes’ into the seawater. The non-feeding larvae typically settle on a suitable 
hard substrate, after they metamorphose into ‘ancestula’ larvae, which become an individual and 
functional zooid (autozooid) that begin a new colony. The colony continues to replicate genetically 
identical zooids by asexual budding to form a juvenile colony [138, 142]. 
1.6.2. Chemical defenses in marine bryozoans 
The marine bryozoans are sessile and benthic marine invertebrate. In particular, cheilostome bryozoans 
have evolved to develop the skeletal structures at both zooidal and colonial levels and their polymorphic 
zooids such as avicularia or vibracula and varicularia are involved to defend against fouling organisms 
and infection by pathogenic microorganisms. Moreover, some marine bryozoan colonies have fragile 
forms including fenestrate, foliaceous and delicate branched and are more vulnerable to predation than 
encrusting species. Therefore, they are more prone to release active chemical compounds or secondary 
metabolites to defend against potential predators including amphipods and fishes [151-154]. 
The marine bryozoan secondary metabolites, bryostatins have significant ecological roles to the Bugula 
neritina larvae, which are free-swimming, soft-bodied and vulnerable to predators. A study 
demonstrated that the crude extracts of B. neritina larvae were unpalatable to fish. Moreover, it was 
shown that when the larvae of B. neritina was consumed by predators and the larvae were regurgitated, 
the metamorphosis of the bryozoan larvae were not hindered [155, 156]. Another group of marine 
bryozoan metabolites, the tamjamines, is a group of alkaloids, isolated from a variety of marine 
invertebrates including the marine bryozoan Sessibugula translucens, ascidians and nudibranchs [157, 
158]. These secondary metabolites serve as an effective chemical defense against carnivorous fish. 
Bryozoan secondary metabolites can be transferred up through the food chain as bryozoans are a dietary 
source for the carnivorous nudibranch Roboastra tigris, Tambja abdere and T. eliora (dietary sources 
of R. tigris). These accumulated bryozoan secondary metabolites are further sequestered by nudibranchs 
and used as a chemical defense against their predator [153, 159]. A mixture of halogenated and non-
halogenated tamjamines have been isolated from the nembrothid nudibranch and its dietary source, the 
bryozoan S. translucens and a study showed that these compounds were deterring the California spotted 
kelpfish Gibbonsia elegans in a fish feeding-aquarium assay. It has been observed that, high amounts 
of tamjamines in the bryozoan S. translucens tend to repel nudibranch predators [160, 161]. 
1.6.3. Chemical diversity in marine bryozoans 
Marine bryozoans are well-known sources of bioactive compounds. Structurally diverse secondary 




sterols, tetracyclic terpenoids and sphingolipids. Many of these compounds exhibit antimicrobial, 
anticancer and antifouling activities [162]. Evidences suggested that, associated bacteria are the true 
producers of many of the secondary metabolites isolated from marine bryozoans [54, 163]. 
Bacterial symbionts in marine bryozoans 
The marine bryozoans are colonized by either pathogenic or beneficial symbionts, and they can be found 
on the surface as biofilm or with in the bryozoan colonies, since bryozoans are filter feeders and are 
predominantly consuming unicellular algae [164-166]. The symbionts live in the funicular cords 
(connective tissues), avicularia (defense) and ovicells (brooding chambers), which are polymorphic 
zooids in bryozoan colonies [167-171]. In some cases, rod and irregular shaped bacteria were observed 
in the particular body part, ‘pallial sinus’ of the bryozoan larvae, Bugula sp. by transmission electron 
microscopy (TEM). This suggests that a vertical transmission of the bacterial symbionts in bryozoans 
are common [167, 172, 173]. For example, the uncultured endo-bacterial symbiont, Candidatus 
Endobugula sertula (E. sertula) are found in the larvae of marine bryozoan B. nertina. The adaptations 
of symbionts on bryozoans ensure lateral/vertical transmission and could possibly be advantageous to 
the bryozoan colonies [174, 175]. The surface associated bacteria on benthic invertebrate bryozoans are 
chemically mediated themselves or within the bryozoan colonies for nutritional exchanging, quorum 
sensing or deterring pathogens [96, 176]. Epibionts are able to colonize and establish biofilm on benthic 
marine bryozoans. An investigation of bacterial diversity in the North Sea bryozoan species Flustra 
foliacea revealed that alpha and gamma Proteobacteria including Pseudoalteromanos, Shewanella, 
Bacillus species, are found on the different body parts (distal, proximal and basal parts) of bryozoan 
colonies. The influence of bacterial colonies might be the production of secondary metabolites in F. 
foliacea. The nutritional relationship between the marine bryozoan, Aquiloniella scabra and their 
symbiotic bacteria has also been studied and suggested that the bacteria in the funicular bodies exchange 
the nutrients. In the sense that the small bristles like internal organs in A. scabra absorb the substances 
that are produced by bacteria. In return, the symbionts consume the mucus produced by a vestibular 
organ in bryozoans [164, 172]. Furthermore, the complex structure and function of the funicular bodies 
in marine bryozoans indicate that, the symbionts actively sway within the tissues of bryozoans and use 
them as an incubator for their growth and multiplications [164]. 
Macrocyclic lactones - bryostatins 
Many natural products isolated from marine bryozoans have been suggested to originate from bacterial 
symbionts or derived from the diet. The bryostatins are well-known cytotoxic compounds isolated from 
the marine bryozoan B. nertina, which are collected from different geographical locations including the 
bay of Florida and China Sea waters [177, 178]. The bryostatins 1-20 share a common twenty-membered 
macro lactone ring with three functionalized terahydropyran rings and they differ predominantly in their 




tetrahydropyran ring. The bryostatins can also be categorized by the presence or absence of a 2,4-
octadienoate moiety at their C-20 positions [177]. Recently, a new macrocyclic lactone, bryostatin 21 
was identified and the novelty of bryostatin 21 is the presence of a single methyl group at C-18 compared 
with other previously isolated bryostatins [178]. 
Bryostatin 1 is produced by a species-specific endosymbiont, Candidatus Endobugula sertula 
(E.sertula). It is Gram-negative γ–proteobacteria, associated with the marine bryozoan B. neitina.[175] 
The biosynthetic gene cluster bryA has recently been found in E. sertula and it is responsible for the 
















Figure 12: The chemical structure of bryostatin 1-20 isolated from marine bryozoan, B. neritina. 
Bryostatins 1-21 exhibit a remarkable range of biological activities, including cognition and memory 
enhancement, cytotoxic, and synergistic chemo-therapeutic activities [178].  Among the 21 known 
macrolides, bryostatin 1 is unique as a protein kinase C (PKC) modulator. Bryostatin 1 modulates 
protein kinase C (PKC) activity with stimulating effects on haematopoietic progenitor cell growth and 
various leukocyte activities. However, due to its toxicity and side effects, bryostatin 1 was discontinued 
as an anticancer agent [54]. Nevertheless, clinical trials (phase I/II) with bryostatin 1 are still ongoing 
and bryostatin 1 has shown significant activity in cognition and memory enhancement and can possibly 
be used as a novel drug for Alzheimer’s disease [179]. 
Alkaloids  
The group alkaloids is one the major secondary metabolites that has been frequently isolated from 




Flustramines: Flustamines are a group of structurally diverse brominated alkaloids and consist of 
pyrroloindoline and indole derivatives. To date, nearly 40 indole and indoline containing secondary 
metabolites have been reported from the North Sea bryozoan Flustra foliacea collected from different 
geographical locations including Scandinavian and Canadian waters. The flustramines exhibit a broad 
range of biological activities, and they have been reported that as being antibacterial, antifungal, muscle 
relaxing, inhibiting non-specific voltage sensitive potassium (K+ ion) channels and acetylcholine 
inhibitory activities [162, 180-189]. The production of secondary metabolites in the North Sea bryozoan 
F. foliacea has been related to their associated bacteria. As described above in the section 5.7.1, the 
bacterial colonies were found in the different body parts of F. foliacea, however, the number of bacterial 
cells was significantly reduced in the growing body parts. This inhibition pattern indicated that the 
secondary metabolites from marine bryozoans could possibly be preventing the microbiofilm [172]. The 
isolated compounds from the North Sea marine bryozoan F.foliacea, dihydroflustramine C and 
flustramine D, exhibit antibacterial activity against Gram-positive bacteria such as Staphylococcus 
aureus, Streptococcus epidermidis and Gram-negative bacteria, Escherichia coli and Pseudomonas 
aeruginosa. In addition to that, flustramine E had antifungal activity. A significant antagonistic effect 










Figure 13: Chemical structure of brominated secondary metabolites from marine bryozoans F.foliacea. 
(Flustramine A, D, dihydroflustarmine C and flustramine E and indole derivatives) 
Tamjamines: Tamjamines are bi-pyrrole alkaloids that have been isolated from the marine bryozoans, 
Bugula dentana and Sessibugula translucens. These compounds have also been reported from the 
ascidian, Atopozoa sp. and their predator nudibranchs [83, 191]. Tamjamines are characterized by two 
pyrrole rings with an enamine moiety at C-5, and a methoxy group at C-4 in many of these compounds, 
the enamine nitrogen is substituted with a saturated short alkyl chain [192]. Besides their ecological 
role, tamjamines alkaloids possess a wide range of biological activities including antitumor, 




The tamjamines are structurally similar to another compound, tamjamine YP1 (substituted with an 
unsaturated alkyl chain), which was isolated from the marine bacterium, Pseudoalteromonas tunicate. 
The biosynthetic gene cluster Tam for the production of tamjamines has been found in P. tunicate. This 
suggested that the marine bacterium, P. tunicate may be present in the tissues or surface of the marine 
bryozoan B. dentana and S. translucens [194, 195]. 
 
Figure 14: Chemical structure of tamjamines A-K from marine bryozoans and a secondary metabolite of bacterial 
symbiont, tamjamine JYP. 
Apart from flustramines and tamjamines, several alkaloids have been isolated from marine bryozoans. 
The brominated indole–imidazole alkaloids, securamines A-I have been isolated from the North Sea 
bryozoan, Securiflustra securifrons. In addition, securines A and B were obtained by dissolving 
securamines A and B in DMSO-d6 [196-198]. The simple indole, 2,5,6-tribromo-N-methylindole-3-
carbaldehyde was isolated form the marine bryozoan, Zoobotryon verticullatum and showed antifouling 
activity against sea urchins embryos. The brominated tryptophan derivative, beta carboline (5-bromo-
8-methoxy-1-1-methyl-beta-carboline), isolated from the marine bryozoan, Cribricellina cribraria, 
exhibited significant cytotoxicity against murine leukemia cell line P-388 and antimicrobial activity 
against Candida albicans and Bacillus subtilis [129]. Pterocellin is a true alkaloid, which contain 
nitrogen in the heterocycle ring and is an amino acid derivative. Pterocellins were isolated from the 
marine bryozoan, Pterocella vesiculosa, collected around the Chicken Island, North of New Zealand. 
Pterocellins possess an unique heterocyclic skeleton (a tricyclic pyrido [4,3-b] indolizine ring system, 
which exhibited cytotoxic activity against murine leukemia cell line P-388 and antimicrobial activity 
against E. coli and C. albicans [199, 200]. Calibugulones are an isoquinoline alkaloid type, 
identified from the marine bryozoan, Calibugula intermis collected from the South Pacific off Palau, 
and displayed significant cytotoxicity against the IC-2WT murine tumor cells [201]. 





Sphingolipids are characterized by a sphingoid base with a long chain fatty acid. They consist of two 
groups such as ceramides and cerebrosides. Two novel sulfate of ceramides (Fig 16) were identified 
from the Japanese marine bryozoan, Watersipora cucullata. Sulfates of ceramide showed a significant 
inhibition against human topoisomerase 1 by inhibiting its DNA binding activity and could be developed 
as inhibitors for topoisomerase 1 for treating cancer [202, 203]. Furthermore, six ceramides were 
reported from the marine bryozoan B. nertina, collected from the South China [204]. 
Figure 16: Chemical structures of ceramides A and B 
Terpenoids and sterols 
A novel tetracyclic terpenoid lactone, murrayanolide was identified from bryozoan, Dendrobeania 
murrayana, collected from Canadian waters. Murrayanolide possesses an unusual C21 skeleton and it 
exhibited significant inhibition against metalloprotease collagenase IV [205]. Sterol is one of the most 
important chemical classes isolated from marine bryozoans. Approximately 20 sterols have been 
isolated from the Bugula neritina species alone [203, 206, 207]. For example, two new oxygenated 
sterols, 3β,24(S)-dihydroxycholesta- 5,25-dien-7-one and 3β,25-dihydroxycholesta- 5,23-dien-7-one 
(Fig 17) were isolated from the marine bryozoan B. neritina which was collected in Daya Bay, 
Guangdong Province, China [130]. It has been suggested that, the potential sources of sterols in B. 















The standard workflow from crude extract to pure compound performed in Marbio has been modified 
based on this thesis requirement (Fig 18).  The workflow is initiated with crude extract and 
prefractionations to bioactivity profiling of isolated compounds. The methods are briefly described 
below.  
 
Figure 18: Schematic workflow of biological and chemical screening.  
The collected bryozoan samples were lyophilized and extracted, fractionated and bioassayed. The crude 
extracts were selected from the preliminary biological and chemical screening. The target compounds 
were isolated, and their structures were elucidated using various spectroscopic techniques (HR-MS and 
1D and 2D NMR). 
1.7.1. Extraction and sample preparation 
The lyophilized marine invertebrates were ground into fine particles to improve the kinetics of extraction 
by increasing the contact surface of the sample with the organic solvent [209]. The powered samples 
were extracted into aqueous and organic (Dichloromethane and methanol) extracts. The crude extracts 
from marine invertebrates are usually complex mixtures and contain large amounts of inorganic salts 
and non-polar compounds along with bioactive components. In order to remove such impurities, the 
crude extracts were fractionated using several techniques including liquid- liquid separation and 
chromatographic techniques. In liquid-liquid partition, two immiscible liquids (polar and non-polar 
solvents) are used to remove certain compounds from the crude extract [210]. The sample was dissolved 
in hexane and methanol and partitioned against water. The hexane and water were used to separate 
lipophilic and hydrophilic compounds [211]. Flash chromatography is another option for the separation 




stationary phase in a prepacked column, which is packed with adsorptive macroporous resins (e.g: 
HP20SS). In this thesis, the crude extracts were pre-purified by liquid-liquid partitions prior to flash 
fractionations or HPLC-HRMS in order to identify and purify the target compounds (described in paper 
1 and 2). The obtained flash fractions were tested for bioactivity [63]. The semi-purified or active 
fractions are subjected to dereplication process as described in section 1.3. 
1.7.2. Isolation by using preparative high-performance liquid chromatography 
(HPLC) 
The main aim of natural product purification is the isolation of target compounds. Isolation is a process, 
which separates a compound or more compounds from each other in a crude extract or fractions. The 
repeated steps of separations provide sufficient amounts of purified compounds that will allow for 
chemical characterization and bioactivity testing. The nomination of target (dereplicated) compounds 
are not only based on the preliminary bioactivity results (e.g: bioassay-guided isolation), but also based 
on potential chemical novelty and abundancy in the crude extracts [64]. The isolation and purification 
of target compounds can be carried out by various chromatographic techniques. In chromatographic 
techniques, the molecules in crude mixture are distributed between two phases, a mobile phase carries 
the extract through a stationary phase. HPLC is one of the most versatile techniques for the efficient 
separation of natural products and it provides high-resolution power that improves sensitivity and 
facilitates the detection the minor components present in the complex crude mixtures. In HPLC, the 
molecules in crude mixture or fractions are forced by liquid mobile phase at high pressure and the 
separation is mainly based on compounds’ distribution between a solid stationary phase and the mobile 
phase. Prep HPLC is commonly used to separate the components of a mixture repeatedly for purification 
purpose [8]. Reverse phase columns are the most common approach for the isolation of MNPs in prep 
HPLC. In the RP HPLC, the mobile phase is significantly more polar than the stationary phase in the 
sense that hydrophobic molecules in the mobile phase tend to adsorb to the relatively hydrophobic 
stationary phase and hydrophilic molecules in the mobile phase tend to elute first [210]. The column in 
RP prep HPLC is mainly packed with C18 (octadecyl) coupled to the silica particle substrate. The 
surface modification of packing material in the column determines the interactions between the target 
compound(s) and the stationary phase. Other types of RP columns can also be used such as phenyl-hexyl 
and fluorophenyl. The separation of compounds in RP prep-HPLC with a C18 are generally performed 
by using two solvents usually water and an organic solvent such as acetonitrile or methanol. The solvent 
system is usually supplemented with acid, in order to improve separation efficiency [66]. Prep HPLC 
combined with mass spectrometry assists the isolation of target compounds. The fraction collector of 
the prep HPLC collects the target compounds through mass triggering. When the eluting compound 




this, the flow of separated compounds from the column splits about 1% to the MS and UV detector and 
remaining 99% proceeds to the fractions collector [66].  
1.7.3. Structure elucidation 
Various analytical spectroscopic techniques such as UV–visible spectroscopy, infrared absorption 
spectroscopy and NMR are often used for determining the chemical structure of secondary metabolites. 
A combination of these techniques provides structural information of the unknown metabolites. 
High Resolution – Mass Spectrometry (HR-MS) analysis  
Mass spectrometry is an analytical technique that aims to determine a molecular mass of a compound. 
A mass spectrometer consists of three components; an ion source, a mass analyzer and a detector. The 
sample is introduced into an ionization source, where the sample molecules are vaporized and ionized. 
These charged ions are transported to the mass analyzer, where they are separated based upon their 
mass-to-charge ratio (m/z).  Finally, the sorted ions pass to a detector that converts the ion energy into 
electrical signals. A data system collects and processes data from the detector. The MS data provides 
the information about molecular masses, relative abundance and isotopic patterns, which can be used to 
calculate elemental composition of the compounds [212]. In this thesis, UPLC-HR-MS with 
electrospray ionization was used. UPLC allows for rapid and efficient separation of complex crude 
extracts, since it operates at high pressures (up to 1200 bar) with small particle size (2 µm) of packing 
material in the column. UPLC provides short analysis times as well as high peak capacity, sensitivity 
and reproducibility [213, 214]. Electrospray ionization (ESI) is the common ionization technique for 
polar compounds. In ESI, the solvent molecules are sprayed into fine droplets (aerosol) and the 
electrically charged particles transfer into gaseous phase ions before they enter to mass analyzer [212]. 
ESI is a soft ionization technique that can be operated both positive and negative mode and it produces 
little fragmentation. HR mass analyzers allows separating ions with similar masses and are used to 
determine molecular mass with high accuracy (e.g: m/z 357.0926) [8]. The detected ions by HRMS are 
plotted as m/z verses relative abundance in percentage (%). 
Nuclear magnetic resonance (NMR) 
Nuclear magnetic resonance is a spectroscopic technique, which is based on the absorption of 
electromagnetic radiation in the radio frequency by nuclei of the atoms. In the presence of a strong 
magnetic field, nuclei such as 1H and 13C are able to absorb the radio frequency energy and they begin 
to resonate at different frequencies. This resonance is used to study the structural information of the 
molecules including the number of carbon and proton atoms and their connectivity. The NMR is 
dependent upon the atomic nuclei having magnetic properties.  1H, 13C are the most commonly studied 
nuclei and have nuclear spins (½).  In the absence of an external magnetic field, each nuclei is randomly 




possible orientations, either align themselves (+½) or against (-½) to the field of the external magnet. 
The electromagnetic radiation of the frequency causes the nuclei to flip from aligning (absorption of 
lower energy) to aligning against (absorption of higher energy) to the magnetic felid. The applied energy 
transfer is possible between ground states to excited state. When the spin returns to its ground state level, 
the absorbed radio frequency energy is emitted at the same frequency level can be measured. The emitted 
radiofrequency signal provides the NMR spectrum of the concerned nucleus. The NMR spectrum is 
plotted by applied radio frequency verses intensity of NMR signal in reference to tetramethylsilane 
(TMS). The proton and carbon spectra provide information about chemical shift, spin-spin coupling 
constant, relaxation time and signal intensity. Chemical shift provides information about the 
composition of atomic group within a molecule (e.g: what type of nuclei whether proton or carbon and 
how many in numbers). Coupling constants provide an information on adjacent atoms in the sense that 
which nuclei are connected to each other and signal intensity provides a quantitative information such 
as atomic ratios within a molecule [8, 214, 215]. In this thesis, the one dimensional and two-dimensional 
NMR experiments were used for the structure elucidation of the bryozoan secondary metabolites 
presented in papers 1 and 2. The 2D NMR experiments were correlation spectroscopy (COSY), total 
correlation spectroscopy (TOCSY), heteronuclear multiple bond correlation (HMBC), heteronuclear 2-
bond correlation (H2BC) heteronuclear single quantum correlation (HSQC). Overhauser effect 
spectroscopy (NOSEY) and rotating frame nuclear overhauser effect spectroscopy (ROSEY). N15 
heteronuclear correlation (HMBC and HSQC). The information from each different NMR experiment, 
used in structure elucidation of isolated compounds, is summarized in a Table, which can be seen below. 
 
1.7.4. Bioactivity profiling of isolated compounds 
After isolation, the bioactivity profile of the pure compounds is determined using different bioassays. 
The bioassays can be biochemical or cell-based assays. Cell-based assay measures the ability of a 
compound to cross the cell membrane and reduced the intracellular metabolic activity within the cells 
or disruption of the cell membrane on cells (e.g: disruption of cell membrane leads to cell death or 
growth inhibition by reducing metabolic process - bacteriostatic).  Alternatively, biochemical assays are 
able to detect and quantify effects on a specific cellular process or metabolic reactions [39, 66]. The 
NMR experiment Information 
1H Identification and number of protons  
COSY Identification of protons that are coupled to each together or neighboring protons 
TOCSY  Identification of coupled proton and identification of spin system 
HSQC Identification of connected proton-carbon 
HMBC Identification of connected proton-carbon by 2 or 3 bonds 
H2BC Identification of protons and proton-bearing carbon spins by two bonds correlations 




disadvantage of biochemical bioassay does not determine compounds’ properties such as membrane 
permeability, cytotoxicity and off targets effects. However, biochemical assays are simple, more 
consistency and direct measurement of defined targets such as enzymes, receptors and cellular proteins. 
The combination of both types of bioassays are useful for bioactivity profiling of isolated compounds 
[66]. In this thesis, the pure compounds were tested with a panel of available bioassays such as 
anticancer and antimicrobial, immune modulatory (anti-inflammatory TNF-α) cell-based assays and, 

































2. Aim of the thesis 
Marine bryozoan is a prolific source of structurally diverse bioactive secondary metabolites. However, 
the total number of natural products isolated from marine bryozoans is limited, and only 78 new 
secondary metabolites from this group have been reported since 2008. The phylum Bryozoa is one of 
the major groups of diverse benthic invertebrates in the high polar-regions. The diversity of Arctic 
marine bryozoans is estimated to be about more than three hundred species, but the number of new 
secondary metabolites isolated from cold-water marine bryozoans is low. Thus, the aim of the present 
study was to find new natural products with novel structures from Arctic marine bryozoans. The 
discovery of new marine natural products can potentially provide new and improved therapeutics for 
human illnesses, along with other innovative products for other industrial activities such as 
nutraceuticals and biotechnology applications. The goal of this thesis was to isolate and to elucidate the 
structures of new secondary metabolites from Arctic marine bryozoans, and to test the isolated 
compounds for potential bioactivities using available bioassays. To achieve this goal, two Arctic marine 
bryozoans, Securiflustra securifurons and Dendrobeania murrayana, were collected from the 
Norwegian coast and investigated using the Marbio marine bioprospecting pipeline. 
The main objectives of this study were, 
Identification of compounds in crude extracts based on either bioactivity or structural features. 
1) Identify new compounds in fractions/crude extract based on either primary screening of 
bioactivity or difference between in other chemical compounds present in various Arctic marine 
bryozoans 
2) Dereplication of the bioactive fractions/crude extract to identify target compounds 
3) Isolate the target compounds 
4) Structure determination of the target compounds 














3. Summary of papers 
Paper I 
 
Priyanka Michael, Kine Ø. Hansen, Johan Isaksson, Jeanette H. Andersen, Espen Hansen.  
 
A Novel Brominated Alkaloid Securidine A, Isolated from the Marine Bryozoan 
Securiflustra securifrons 
 
Molecules, 2017, 22, 1-11. 
 
A novel mono brominated tyrosine derivative, securidine A (Fig 19) was isolated from the Arctic marine 
bryozoan, Securiflustra securifurons. Flash fractions from an aqueous extract of S. securifrons showed 
cytotoxicity against the A2058 human melanoma and HT29 colon adenocarcinoma cell lines. Chemical 
investigation of the bioactive flash fractions using UPLC-HRMS revealed the presence of a mono 
brominated compound. The compound had an elemental composition that did not match any known 
marine natural products, so it was isolated through mass guided fractionation on semi-preparative 
HPLC. The chemical structure of the compound was elucidated by spectroscopic (1D and 2D NMR) 
techniques. The alkaloid compound, named securidine A, had a novel structure consisting of a 
brominated tyrosine, and it was not structurally related to any previously described compounds from S. 
securifurons. To test potential bioactivities of the pure compound, securidine A was tested against cancer 
cell lines using an MTS based anticancer assay. Securidine A did not show any significant cytotoxicity 
against the human melanoma or colon adenocarcinoma cell lines at 100 µM. Securidine A was further 
evaluated with various bioassays including antibacterial activity against Staphyloccoccus aureus, 
Escherichia coli, Pseudomonas aeruginosa, Enterococcus faecalis or Streptococcus agalactiae (gr.B), 
inhibition of protein tyrosine phosphatase B (PTP-1B) for antidiabetic activity as well as biofilm 
inhibition against S. epidermidis (all assays tested up to 100 µM). The compound did not show any 













Priyanka Michael, Espen Hansen, Johan Isaksson, Jeanette H. Andersen, Kine Ø. Hansen. 
Dendrobeaniamine A, A New Alkaloid from the Arctic Marine Bryozoan, Dendrobeania 
murrayana.  
 
Natural Product Research, 2019, 1-6. 
 
 
A chemical investigation of the crude organic extract of the Arctic marine bryozoan Dendrobeania 
murrayana, collected off the Norwegian coast, led to the isolation of a new secondary metabolite, 
dendrobeaniamine A (Fig 20). Dendrobeaniamine A is a lipo-amino acid, which consists of a C12 linear 
fatty acid that is connected to a positively charged L-arginine amino acid. A detailed chemical analysis 
of the organic crude extract of D. murrayana using UPLC-HRMS revealed the presence of a prominent 
peak at Rt 5.7 min with a m/z 369.2861. The calculated elemental composition was C19H36N4O3 and it 
gave no hits when searched for in relevant databases (Dictionary of marine natural products and 
ChemSpider). The compound was isolated through mass guided fractionation using semi-preparative 
HPLC. The chemical structure of dendrobeaniamine A was determined by using spectroscopic methods 
(1D and 2D NMR). The amphipathic structure of dendrobeaniamine A was evaluated for bioactivity 
based on cellular and biochemical assays but the isolated compound did not show cytotoxic, anti-


















Kine Ø. Hansen, Ida Kristine Ø. Hansen, Celine S. Richard, Priyanka Michael, Marte Jenssen, Jeanette 
H. Andersen, and Espen Hansen 
 
Antimicrobial Activity of Securamines from the Bryozoan, Securiflustra securifrons 
In revision, submitted to Marine Drugs. 
 
Marine bryozoans are sessile and benthic invertebrates. To prevent attacks from pathogenic bacteria, 
they are known to utilize chemical defense mechanisms. The present study investigated the 
antimicrobial activity of a series of previously isolated secondary metabolites, securamine C (4), E (5) 
and H – J (1 - 3), isolated from the Arctic marine bryozoan Securiflustra securifrons against pathogenic 
bacteria. In addition, securidine A (6) was tested for synergistic antibacterial effect in combination of 
securamine H (1) against five pathogenic bacterial strains. The flash fractions (one to eight) from the 
organic extract of S. securifrons were screened for antibacterial activity and fraction three was found to 
be active against the pathogenic bacterium, Streptococcus agalactiae (gr.B). Chemical investigation of 
this fraction using UPLC-HRMS revealed that it contained several variants of the securamines along 
with abundant amounts of brominated tyrosine derivative, securidine (6). Compound 6 was previously 
determined to be inactive against bacteria and biofilm formation at 100 µM. Compounds, H (1), I (2) 
and E (5) were found to be active against all test G+ strains. The most potent antibacterial activity was 
exhibited by compound 1 with the lowest MIC measured value of 3.13 µM. The mode of action of 1 
was investigated by using modified variants of the G+ bacteria, Bacillus subtilis and the G- bacteria, E. 
coli. Compound 1 did not affect B. subtilis viability by bacterial membrane integrity disruption but it 
was found to be active against B. subtilis by interfering with their metabolic machinery. Therefore, 
Secramine H (1) was tested for its ability to inhibit several metabolic processes including DNA 
replication, transcription and folic acid synthesis. We were not able to identify the intracellular target of 
securamine H (1). Finally, securamine H (1) and securidine A (6) were tested for synergistic effects 
against G+ and G- pathogenic bacterial strains, since both compounds were largely present in the 







4. General discussion 
The phylum Bryozoa is well-known to produce diverse marine natural products. Exploring untapped 
geographical sources, including cold waters bryozoans, offers new natural products with unusual 
chemical structures. Bryozoans are the most dominant benthic marine invertebrate in the Arctic Ocean. 
Marine bryozoans in Svalbard waters (between 50° to 70°N) are mainly represented by Arctic and boreal 
Arctic species [145]. Nevertheless, a high number in Arctic bryozoan species have received little 
attention with regard to studies of their natural products compared to tropical species [216, 217]. The 
evolution of chemical diversity in benthic marine invertebrates is not mainly driven by predator 
interaction, which is high in tropical waters, but there are number of interactions constantly involved in 
the complex marine ecosystem, which are accountable for the biosynthesis of natural products [71]. In 
particular, psychrophilic organisms in the Arctic regions possess diverse array of biochemical and 
physiological adaptations towards to various external parameters including low temperature, strong 
winds and high ultraviolet radiation. These adaptations are often accompanied by modifications to both 
gene regulation and metabolic pathways and increasing the possibility of finding new secondary 
metabolites with pharmaceutical interest  [71, 218]. 
At the commencement of the present work, two boreal arctic bryozoan species collected from the 
Svalbard waters were extracted and investigated for new natural products (paper 1 and 2). The 
antibacterial activity of the isolated compounds from S. securifrons and their potential synergistic effects 
were also studied (Paper 3). The biological samples were provided by the Norwegian national marine 
biobank Marbank (Institute of Marine Research, Tromsø, Norway), and they were collected off the coast 
of West Spitzbergen and in Vesterålsfjorden by trawl and scuba diving at a depth range between 
approximately 30-70 meters. The marine organisms were immediately frozen at -23°C and lyophilized 
before extraction. The collected bryozoans had erected forms and were weakly calcified, belong to the 
class Gymnolaemata and order Cheilostomata [137].  The images of the bryozoans species Securiflustra 
securifrons (belongs to Flustridae family) and Dendrobeania murrauyana (Bugulidae family) can be 
seen in Fig 21. These sample materials provided sufficient amount of biomass for isolating the target 
compounds in quantities, which allowed for characterizing their molecular structures as well as a limited 
number of bioactivity testing. A total amount of pure compound securidine A isolated from S. 
securifrons was 2.65 mg and dendrobeaniamine A isolated from D. murrayana was 2.5 mg. For the 
initial biological evaluation, the isolated compounds were tested with biochemical and cell-based assays, 
which are available in the Marbio laboratory. Any bioactivity of pure securidine A and 


















Figure 21: An image of marine bryozoans S. securifrons (to the left) and D. murrayana (to the right)  
Photo: Robert Johansen, Marbank 
4.1. Supply issues 
A sufficient supply of pure compounds is a major challenge in marine natural product drug discovery 
because the abundance of secondary metabolites in marine invertebrates is usually very low. For 
example, bryostatin 1 is a lead compound for the development of anticancer drug, and it was isolated 
from the marine bryozoan Bugula neritina. For structural elucidation, a total of 500 kg of marine 
bryozoans was harvested and the wild harvesting of B. neritina provided very low yield (unpublished) 
of pure bryostatin 1, but the yield of bryostatins 2 and 3 were 314 mg and 81.5 mg respectively [219]. 
For biological characterization by the National Cancer Institute, USA, about 14 tons of source organism 
were made by ‘hand collection’, which provided only 18 g of bryostatin 1 (0.00014% yield) [220]. To 
obtain large quantities of pure compound and constant supply for drug development, bryostatin 1 was 
originally produced through aquaculture and mariculture. Nevertheless, both methods produced 
approximately 100 g of bryostatin 1 per year, which was not economically feasible ($ 30,000 per gram 
of bryostatin 1). Therefore, bryostatin 1 was totally synthesized in 1990. In addition, bryostatin 1 was 
simplified to a more potent analogue based on the specific interaction with the target protein [221]. 
Another example is the FDA approved drug Ecteinascidin 743, which was isolated from the colonial 
ascidian Ecteinascidia turbinata and reported for its antitumor activity in 1969. The yield of pure 
compound was 0.0001% [109]. In order to overcome the supply issue for drug development, the marine 
invertebrate was cultivated in Mediterranean aquafarms during 1998-2003 and produced a total of 100 
metric tons of tunicate biomass [221]. For commercialization purpose, the complex compound, 
trabectedine was totally synthesized through 32 steps in 1996 for avoiding the dependency on one 




scale. Therefore, this compound was obtained by semi-synthesis through fermentation of the bacteria 
Pseudomonas fluorescens [114]. The isolated pure compounds securidine A and dendrobeaniamine A 
are new natural products, as they have not been reported earlier. To isolate more of the compounds for 
more extensive bioactivity studies, the bryozoan species can be recollected off the coast of northern 
Norway, since they are found in abundant amounts in the North Sea and the Barents Sea [137]. However, 
the content of secondary metabolites in marine organisms varies depending on seasonal changes, effects 
of predators and locations. Notably, dendrobeaniamine A was not present in D. murrayana specimens 
collected in off the Coast of Bear Island (data not shown). Securidine A and dendrobeaniamine A can 
also potentially be synthesized chemically to obtain larger amounts.  
4.2. Preparation of crude extract into fractions and bioactivity screening 
Briefly, the collected Arctic bryozoans S. securifrons and D. murryana were extracted with aqueous and 
organic solvents. As referred in paper 1, the freeze-dried and pre-purified aqueous extract of S. 
securifrons were prefractionated into eight fractions by using column chromatography with a flash 
purification system. The extract was eluted with a gradient of water, methanol and acetone and the 
obtained fractions were screened for initial bioactivity using melanoma and colon carcinoma cell lines. 
The active fractions four and five were nominated for dereplication. In another approach, chemical 
screening was used to identify new natural products in the pre-purified organic extract of D. murrayana 
as described in paper 2. Both methods revealed the importance of dereplication in order to avoid 
reisolation and characterization of previously reported compounds. In the chemical screening, the 
isolated new natural product was not defined by its bioactivity in the initial examination. In contrast, 
bioassay guided isolation was defined by the bioactivity that was used in the bioassay when isolating 
the target compounds. Natural products are viewed as privileged structures selected by evolutionary 
pressures and able to interact with specific targets and the bioactivity of new isolated compounds can 
be discovered at a later stage. For example, the NFkB inhibitor hymenialdisine, isolated from the marine 
sponges Acanthella sp and Axinella sp. in 1982, did not exhibit any significant bioactivities in the initial 
examination. In 2000, it was shown to be an ATP competitive inhibitor of multiple kinases [222, 223]. 
Nevertheless, both methods are efficient for identifying new natural products with interesting chemical 
structures.  
4.3. Dereplication of crude extracts of S. securifrons 
The fractions four and five of the extract of S. securifrons displayed cytotoxic activity (Paper 1). The 
chemical analysis of flash fractions using UHPLC-HR-MS revealed that a compound contained a single 
bromine. The mono brominated compound was named securidine A and the mass of the protonated 
molecule was m/z 357.0858 ([M+H]+). The calculated protonated elemental composition of securidine 




dereplicated compound securidine A was isolated through prep-HPLC in order to obtain adequate 
amount for chemical and biological characterization.  For this purpose, the aqueous crude extract of S. 
securifrons was pre-purified by liquid-liquid partition and the methanol phase, which contained the 
target compound securidine A, was collected and reduced to dryness and resuspended into 80% 
methanol. Securidine A was isolated through mass-guided fractionation, and the mass of protonated 
securidine A (357 Da) was used as a collection trigger. Initial purification of secruidine A was achieved 
by a RP C18 HPLC column with a 10 minutes gradient of acetonitile from 10% to 40%. For a second 
purification step, the collected fraction was dried and redissolved in 80% methanol and injected onto a 
phenyl-hexyl column. Securidine A was eluted with a 10 min gradient of acetonitrile from 10 to 34%. 
The molecular structure of securidine A was solved based on a number of 1D and 2D NMR experiments 
as described in paper 1.  
4.4. Bioactivity profiling of securidine A 
Securidine A is a brominated tyrosine derivative. Securidine A is not structurally similar to the other 
halogenated indole imidazole alkaloids (securamines A-J) which were isolated from S. securifrons 
collected in the North Sea (see paper 1 and see reference in [198]. Many marine organisms including 
ascidians and sponges are well-known to produce brominated tyrosine derivatives, which have been 
found to have antibacterial (e.g: synoxazolidinone) and acetylcholinesterase (e.g: pulmonarin B) and 
antifouling (e.g: barettin) properties (Fig 22).  These compounds have different substitutions but are 
structurally related. The β-phenylethylamine compounds, amathamides have been reported from the 
marine bryozoan Amathia sp. This type of alkaloids is presumably derived from amino acid and 
biosynthesized through biochemical reactions such as specific incorporation of halogens and 
methylation [224, 225]. The structures of these secondary metabolites share a common molecular 
skeleton.  The β-phenylethylamine compounds isolated from bryozoans are known for their bioactivities 
such as antitrypanosomal, anthelmintic and cytotoxic activities [176, 224]. However, no bioactivity of 
securidine A was found against melanoma, adenocarcinoma and breast cancer cell lines nor G+ and G- 
pathogenic bacteria. It also showed no inhibition of protein tyrosine phosphatase 1B (PTPT-1B) for 













On the other hand, the flash fractions of the organic crude extract of S. securifrons were screened for 
antibacterial activity against Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, 
Pseudomonas aeruginosa and Streptococcus agalactiae (gr.B) at 250 µg/ml. Fraction three was 
found to be active against G + bacteria S. agalactiae. The chemical analysis of the flash fraction 
using UHPLC-HR-MS showed that the fraction contained a various group of compounds (securamines 
C, E and H-J – reported earlier, see reference in [198] along with securidine A. The series of securamines 
was present in low amounts, while securidine A was found to be abundant (Fig 23). In many cases, the 
presence of major compounds might mask the bioactivity of minor compounds [53] or synergistic 
interaction between multiple components might potentiate the bioactivity each other or loss of the 
bioactivity also known as antagonistic effect [226]. To address this, securamine C, E, H, I and J and 
securidine A were tested for antibacterial activity. Securidine A was found to be inactive against G + 
and G- bacteria.  The pure compounds securamines 1-5 were tested against G + and G - pathogenic 
bacteria and yeast strains as well as the ability to inhibit biofilm formation in Streptococcus epidermidis 
was also studied at the highest concentration 50 µM (paper 3). The securamines H, I and E displayed 
antibacterial activity against G+ positive bacteria. Among these, securamine H was the most 
active against B. subtilis, S. aureus, E. faecalis, S. agalactiae and the MIC value was ranging from 
6.25 µM to 3.13 µM. Therefore, securamine H was chosen for mode of action studies with 
modified variants of G + bacteria B. subtilis and G- bacteria E. coli. These studies revealed that 
the cell viability of B. subtilis was not affected by securamine H through membrane integrity 
disruption at the highest concentration. Nevertheless, securamine H reduced the metabolic 
activity of this G+ bacteria. Furthermore, securamine H was investigated for its interference 
with bacterial intracellular metabolic process and no activity was observed. To address any 
synergistic interactions, the minor compound securamine H and the major compound securidine 
A were assayed using a checkerboard titration method against pathogenic strains mentioned 
above. Synergistic combination of two or more natural products might significantly enhances 
the overall effect. However, no synergistic effect was not observed between securamine H and 
securidine A against S. aureus, E. faecalis and S. agalactiae. 
Figure 23: The base peak intensity chromatogram of flash fraction three of the organic extract of S. 
securifronsshowed the presence of several securamines, including securamine H, I, C and E (1, 2, 4 and 5) and 




4.5. Dereplication and bioactivity profiling of dendrobeaniamine A 
In the chemistry-guided isolation, the organic crude extract of D. murrayna was directly analyzed by 
UPLC-HR-MS. This extract was found to contain a unique and abundant peak eluting at Rt 5.7 min (Fig 
24) with a m/z of 369.2861 ([M+H]+), and the calculated protonated elemental calculation was 
C19H36N4O3. When searching databases, the elemental composition of the target of compound did not 
match to any previously reported compounds and we presumed that the compound was novel and it was 
named dendrobeaniamine A. The isolation of dendrobeaniamine A was achieved through mass-guided 
fractionation by utilizing RP HPLC C18 (10 µM, 10 mm ×30 mm), and fluorophenyl (5 μm, 10 mm×250 
mm) columns. The structural elucidation of dendrobeaniamine A was done by 1D and 2D NMR 
experiments as described in paper 2. 
 
 
Figure 24: ESI+ base peak intensity chromatogram of the organic extract of D. murrayana analyzed by UHPLC-
HRESIMS. The arrow indicates the prominent peak at Rt 5.7 min. 
Dendrobeaniamine A is a simple lipo-amino acid molecule also known as acyl amino acid, which 
contains one fatty acid and one amino acid conjugated by an amide bond. Lipo-amino acids are mostly 
found in bacteria and marine organisms, in particular marine invertebrates including mollusks and 
bryozoans. This acyl amino acid may be generated by conjugation of fatty acids and amino acids or may 
be metabolites of the corresponding phospholipids. The addition of amino acid into the structures of 
membrane lipids increases structural and chemical diversity [227]. The acyl amino acid conjugates may 
possibly be formed by means of excretion and detoxification of excess amount of their metabolites (e.g: 
ammonia-NH4 and nitric oxide-NO) under abiotic stress conditions such as nitrogen saturation, low 
temperature and nutrient deficiency. In order to reduce abnormal concentrations of normal cellular 
constituents and to maintain the basic metabolism under stress circumstances, the organisms are possibly 




Acyl amino acids have been shown to be biologically active such as antibiotic, anti-inflammatory, 
antioxidant and cytotoxic to mammalian cells [229]. Such bioactivities are based on the degree of 
unsaturation in fatty acyl chains and their solubility. The structural features of dendrobeaniamine A 
is similar to amphipathic molecules that usually contain at least two long-chain acyl or alkyl residues 
in order fulfill the basic requirement of antibacterial activity. However, dendrobeaniamine A did not 
exhibit antibacterial or antifungal activities at the highest concentration (135.68 µM) against S. 
aureus, E.coli, P. aeruginosa, E. faecalis or S. agalactiae and C. albicans nor against the biofilm 
inhibition ability of S. epidermis. This might be due to its mono-unsaturation (double bond) with the 
cis configuration, which is important for the flexibility of compound. Moreover, the zwitterionic nature 
of dendobeaniamine A may result in ionic bond formation between hydroxyl group and charged 
guanidine group, which is probably decreasing the membrane permeability. Dendrobeaniamine A was 
evaluated for its ability to inhibit the release of cytokine tumor necrosis factor (TNF α) from the human 
acute leukemia monocyte cell line (THP-1) at 10 µM and the compound did not show anti-
inflammatory effect. Dendrobeamine A was also evaluated for its antioxidant effect using oxygen 
radical absorbance capacity (ORAC) assay and no significant activity was observed at the highest 
concentration. The structural features and bioactivity of dendrobeaniamine A was compared with two 
other structurally similar compounds, a synthetic antibacterial compound lauric arginate and cytotoxic 
natural product spermidine, isolated from coral Sinularia brongersmai (in paper 2). These three 
compounds differ each other by the presence and absence of specific substituents (Fig 25). As 
production of secondary metabolites is energy consuming, the natural function of dendrobeaniamine A 
is most likely to provide beneficial effect for the producing organisms by acting as a repellent to 
pathogen or predators, in competition for space of to protect against abiotic factors [230]. 
 
  






4.6. Future perspective 
This work shows that Arctic marine bryozoans is a promising source for new molecules with novel 
structures. The compounds investigated in this thesis are new secondary metabolites, isolated from 
Arctic benthic marine bryozoans. The addition of these new secondary metabolites increases the 
structural and chemical diversity of natural products. Possible re-collection of the bryozoans from the 
Arctic Ocean may allow for extensive biological activity studies of the isolated compounds, or 
alternatively they could be chemically synthesized. 
5. Concluding remarks 
Coldwater marine bryozoans is a potential source for new secondary metabolites, and the abundance of 
marine bryozoans in Arctic waters is high. However, the chemical diversity of natural products varies 
between the species or within the species depending on geographical areas. Investigations of secondary 
metabolites from Coldwater marine bryozoans have been limited in numbers. This work describes the 
search for new natural products from Arctic bryozoans. Two new secondary metabolites were isolated 
from Arctic marine bryozoans using two different approaches. The bioassay-guided isolation yielded a 
brominated tyrosine derivative from securiflustra securifrons and chemistry guided isolation yielded the 
conjugated fatty amino acid molecule from Dendrobeania murrayana. Both alkaloids were inactive in 
the limited number of bioassays in which they were tested. The major compound securidine A in the 
organic crude extract of Securiflustra securifrons did not mask the bioactivity of the minor compounds, 
the securamines, and no synergistic effect was observed. The bioactivity of both novel molecules 
securidine A and dendrobeaniamine A should be further investigated with suitable bioassays.  
The secondary metabolites isolated from marine invertebrates can be produced by the invertebrate itself, 
but they can also be derived either from their diet or from microorganism living within the tissues of the 
marine invertebrates. The chemical diversity in benthic marine invertebrates are enormous, even a single 
animal can be a source of many compounds [231]. Even though the ecological functions of these 
secondary metabolites in many cases is cryptic to us, their potential bioactivities can be exploited for 
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Abstract: A novel brominated alkaloid, Securidine A, was isolated from the cold water marine
bryozoan Securiflustra securifrons. Securidine A was isolated using semi-preparative HPLC, and
the structure was elucidated by spectroscopic methods. The isolated Securidine A was tested for
cytotoxic, antibacterial, and anti-diabetic activities as well as for its potential for inhibition of biofilm
formation. No significant biological activity was observed in the applied bioassays, thus expanded
bioactivity profiling is required, in order to reveal any potential applications for Securidine A.
Keywords: secondary metabolites; marine invertebrates; marine bryozoans; Securiflustra securifrons;
Securidine A; biological activity
1. Introduction
Marine organisms are considered to be a rich source for natural products, and currently almost
50,000 marine natural products are reported in the Dictionary of Marine Natural Products [1].
A statistical analysis of marine natural products discovered between 1985 and 2008 estimates that
approximately 75% of the compounds are isolated from sessile and soft-bodied invertebrates including
sponges, ascidians, cnidarians, mollusks and bryozoans [2,3]. In order to protect themselves from
predators and to compete for space and food, many invertebrates have evolved the ability to produce
secondary metabolites as a chemical defense, which increase their ability to survive, grow, and
reproduce [4,5]. Bryozoans, or moss animals, are aquatic invertebrates that belong to the phylum
Bryozoa (Polyzoa). They are sedentary and filter feeders. These colonial organisms consist of tiny
intercommunicating individuals called zooids [6]. Bryozoans are widely distributed in tropical and
temperate marine waters [7], and are common fouling organisms on marine substrates [6]. The phylum
consists of 3 classes, 4 orders, 187 families, and 808 genera, and approximately 8000 species are
described, most of them are observed in marine habitats [8,9]. Marine bryozoans are known to produce
a significant number of biologically active secondary metabolites, including macrolides, alkaloids,
sterols, and heteroatom-containing compounds [3,10] that possess antitumor [11], antibacterial [12,13],
and muscle relaxant activities [14]. The well-known bioactive compound bryostatin 1 is a macrolide
isolated from the marine bryozoan Bugula neritina, and it is proven to be an antineoplastic agent [15].
Secondary metabolites isolated from marine bryozoans have been extensively reviewed [6,8,16,17].
In the present study, we isolated the novel mono brominated tyrosine derivative Securidine
A (1) from the marine bryozoan Securiflustra securifrons. S. securifrons (Pallas, 1766) is a temperate
and subtidal species abundant in the North Sea [18,19], and the encrusting basal portion of the
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colonies are attached to hard substrates such as stones and shells. In previous reports, seven
halogenated indole-imidazole alkaloids, Securamines A–G and Securines A and B (obtained by
dissolving Securamines A and B in DMSO-d6), have been isolated from S. securifrons, but no biological
activities were recorded for any of these compounds. The halogenated Securamines A–G (Figure 1)
differ from each other by the presence and absence of a bromine substitution or a number of bromine
substitutions in the benzene ring. [20,21]. These compounds are structurally similar to chartellines
A–C and chartellamides A and B, isolated from another marine bryozoan Chartella papyracea. Both
species belong to the Flustridae family (Order: Cheilostomata). Many of the Cheilostome bryozoans
including S. securifrons, C. papyracea, and Flustra foliacea are producing indole alkaloids and brominated
alkaloids [12,20–32]. However, the isolated new brominated alkaloid, Securidine A (1) is a novel
structure (Figure 1), which is not structurally similar to any other listed compounds of S. securifrons.
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2. Results and Discussion
The marine bryozoan S. securifrons was collected in April 2014 in the North Sea. Securidine A (1)
was isolated from the aqueous extract of S. securifrons through stepwise fractionation. The lyophilized
animal material was ground and extracted with ultrapure water. The freeze-dried aqueous extract was
pre-fractionated using column chromatography with a Biotage SP24 HPFC flash purification system.
The extract was eluted with a gradient of H2O/CH3OH/CH3-CO-CH3 and the fractions were assayed
for cytotoxicity against melanoma (A2058) and colon adenocarcinoma (HT29) cell lines using an MTS
based anticancer assay. Flash fractions four and five showed cytotoxic activity. UPLC-HR-MS analysis
of these fractions, followed by isotopic pattern examination of the eluting compounds, revealed the
presence of a mono brominated compound. For the isolation, the aqueous extract was injected onto
semi-preparative RP-HPLC C18 column and Securidine A (1) was eluted with a 10 minutes gradient,
changing from 10% to 40% CH3CN over 10 minutes. For the second purification step, a Phenyl-Hexyl
prep HPLC column was used with a 10 min gradient, changing from 10% to 34% CH3CN.
The HR-MS analysis suggested that Securidine A (1) contained a bromine. The molecular formula
was determined to be C14H21BrN4O2, corresponding to the protonated molecular peak at m/z 357.0858
([M + H]+, calculated m/z 357.0926), suggesting six degrees of unsaturation. A database search
indicated that the isolated compound was novel, and its structure was solved based on a number of
1D and 2D NMR experiments.
Interpretation of the available 1D 1H (presat, 1DNOE and excitation sculpting), 1D 13C,
HMBC, ME-HSQC, H2BC, COSY, and ROESY (Supplementary materials Figures S1 to S6) led to
an unambiguous structural elucidation of 1. Examination and comparison of the 1D 13C, HSQC,
and HMBC showed that 1 had 14 carbons consisting of one methyl group, five methylenes, three
methines, and five quaternary carbon atoms. Two 1H resonances, H-10 and H-15, were identified
as NH groups based on the absence of any 1JCH, broadened line widths and deshielded chemical
shifts. Three methines indicated the presence of a disubstituted phenyl ring attached to the main chain.
The methyl group protons (δH 3.84) showed HMBC correlation to the quaternary C-2 (δC 156.2) as
well as ROESY correlation to the H-3 (δH 6.96) methine proton. The relatively deshielded chemical
shift value of the methyl protons (δH 3.84) was assigned as the protons of a methoxy group. The high
chemical shift value of C-2 (δC 156.2) further confirmed this. COSY and ROESY correlations between
H-3 (δH 6.96) and H-4 (δH 7.22) as well as a shared coupling constant of 8.6 between the two, places C-3
and C-4 next to each other. Additionally, the H-3 methine showed HMBC correlation to a halogenated
quaternary carbon (C-5, δC 112.2), the quaternary C-7, (δC 130.5) as well as to the final methine carbon
(C-6, δC 134.5). The distinction between C-7 and C-5 was made based on their chemical shift values
and a 2JCH from C-5 to H-6, which is commonly observed from halogenated carbons but not from
carbons in phenyl rings further away from heteroatoms. The H-8 (δH 3.41) methylene showed ROESY
and HMBC correlations to the protons and carbons in position 4 (δH 7.22, δC 130.2) and 6 (δH 7.47,
δC 134.5), placing it in ortho position to C-4 and C-6 in the phenyl ring. The phenyl group was
thus methoxy-substituted in the para position and brominated in the meta position, while and the
main chain of the molecule was attached to C-7. The H-8 (δH 3.41) protons further showed a HMBC
correlation to a deshielded quaternary carbon (C-9, δC 173.7), characteristic for a carbonyl carbon.
HMBC correlations were observed to H-10 (δH 8.20) from C-9 and to H-10 from C-11 (δC 39.8). COSY
and ROESY correlations were observed between the methylene groups in the 11 (δH 3.20, δC 39.8)
and 12 positions (δH 1.56, δC 27.5). The same correlations were observed between the methylene
groups in position 13 (δH 1.55, δC 27.0) and 14 (δH 3.16, δC 42.0). The methylene groups in the 12 and
13 position were near isochronous, but could be distinguished by their respective couplings to H-11
and H-14 in H2BC and COSY. H-14 further correlated with the quaternary C-16 (δC 158.8) in HMBC
spectra. H-13 (δH 1.55) and H-14 (δH 3.16) both showed ROESY correlations to H-15 (δH 7.57). This,
in addition to a COSY correlation between H-14 and H-15, places a NH-group in the 15 position. Thus,
the remaining part of the chemical formula was N2H3, leaving the only possible structural solution to
be the attachment of an NH- and an NH2- group to C-16. The deshielded shift value of C-16 (δC 158.8)
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was in good agreement with this conclusion (Table 1). Selected 2D correlations utilized in determining
the structure of 1 are shown in Figure 2. The compound was named Securidine A.
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Table 1. NMR spectroscopic data (600 Hz, methanol-d3).
Position δC, Type δH (J in Hz) COSY 1H, 13C-HMBC b 1H, 13C H2BC ROESY
1 56.6, CH3 3.84, s 2 3
2 156.2, C
3 113.1, CH 6.96, d (8.6) 4 2,5,7 4 1,4
4 130.2, CH 7.22, dd (8.6, 2.3) 3,6 2,3,6,8 3 3,8
5 112.2, C
6 134.5, CH 7.47, d (2.3) 4 2,4,5,8 8
7 130.5, C
8 42.4, CH2 3.41, s 4,6,9 4,6,10
9 173.7, C
10 8.20, s 11 9,11 11 8,11,12 w
11 39.8, CH 2 3.20, q (6.4) 10,12 9,(12/13) d 12 10,12
12 27.5, CH2 1.56, m c 11 (11/14) d 11 10 w,11
13 27.0, CH2 1.55, m c 14 (11/14) d 14 14,15 w
14 42.0, CH2 3.16, m c 13,15 16,(12/13) d 13 13,15 w
15 7.57, s 14 14 13 w,14 w
16 158.8, C
a 1H 1D, 13C, 1H, 1H-COSY, 1H,13C-HMBC (full and band selective) spectra are included in the supplementary data,
Figures S1–S6 (Supplementary materials). b 1H 1D, 13C-HMBC correlations are from the proton(s) stated to the
indicated carbon; c Overlapping and/or broadened peaks impeding complete multiplet analysis. Chemical shift
extracted from 1H, 13C-HSQC, 1H, 13C-HMBC and/or 1H, 13C-H2BC; d ambiguous correlations in HMBC, C12 and
C13 assignment based on H2BC correlations (Figure S4); w Weak correlations.
Bioactivity
The pure Securidine A (1) was ev luated for its biologic l activity in a selection of bioassays
including anti-cancer and anti-bacterial activity, inhibition of protein tyrosine phosphatase 1B (PTP-1B)
for anti-diabetic activity, as well as for inhibition of biofilm formation.
Securidine A (1) was assessed for its cytotoxicity against three cancer cell lines (A2058 melanoma,
HT29 colon adenocarcinoma and MCF7 breast carcinoma) by the MTS method, since flash fractions of
the extract from S. securifrons showed anticancer activity against A2058 melanoma and HT29 colon
adenocarcinoma cancer cell lines in the MabCent screening program [33]. However, the isolated
compound, Securidine A (1), did not show any significant activity against the cancer cell lines at
50 µM (17.87 µg/mL) or 100 µM (37.73 µg/mL). Securidine A (1) was also tested for its antibacterial
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activity, and no activity was seen against Staphyloccoccus aureus, Escherichia coli, Enterococcus faecalis,
Pseudomonas aeruginosa, or Streptococcus agalactiae.
Securidine A (1) is a brominated tyrosine derivative. It is structurally related to two other
brominated tyrosine derivatives, Pulmonarin B (2) and Synoxazolidinone B (3) (Figure 3), both isolated
from the sub-Arctic ascidian Synoicum pulmonaria [34,35]. Pulmonarin B (2) contains a quaternary
ammonium group in the side-chain instead of the guanidine group of Securidine A (1) and Pulmonarin
B (2) did not have any antibiotic or cytotoxic activity. Both Securidine A (1) and Synoxazolidinone B
(3) have a guanidine group in the side chain, but Synoxazolidinone B (3) has a central 4-oxazolidinone
core, linking a di-brominated tyrosine derivative to an arginine [36]. Synoxazolidinone B (3) is active
against the Gram-positive bacteria, methicillin resistant S. aureus. Macherla et al. suggested that a
4-oxazolidinone core is a good pharmacophore for antibacterial activity [36]. The difference between
Securidine A (1) and Synoxazolidinone B (3) in activity against bacteria might thus be explained by the
lack of a central 4-oxazolidinone core in Securidine A (1). Moreover, most of the antimicrobial peptides
or alkaloids are amphipathic molecules, including Synoxazolidinone B, which displays two cationic
groups and two bulky lipophilic groups in order to fulfill the structural requirements of antibacterial
activity [37–39]. A study of the pharmacophore of small antibacterial peptides demonstrated that
one cationic group as well as a minimum of two bulky groups were required for activity against
Gram-positive staphylococci [40].
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Figure 3. The structurally related compounds Securidine A (1), Pulmonarin (2), and Synoxazolidinone
B (3).
The effect of Securidine A (1) against P l exa ined, since PTP-1B is regar ed s a
promising target for the treatment of diabet s [41]. However, no inhibition of PTP-1 at
50 µM or 100 µM. Many potent antifouling comp unds are brominated tyrosine derivatives that have
cationic guanidine or guanidine-like groups [42]. Nevertheless, no inhibition of biofilm formation by
Staphylococcus epidermidis was found at 100 µM.
3. Materials and Methods
3.1. Animal Material
The marine bryozoan Securiflustra securifrons (Palllas, 1766) was collected by an Agassiz trawl at
73 m depth from west Spitzbergen (71.0759◦ N, 24.4355◦ E) in April 2014. The fresh sample weighed
336.01 g and was frozen immediately at −23 ◦C. The specimen was identified by Norwegian marine
biobank Marbank (Institute of Marine Research, Tromsø, Norway) and they have a taxonomical
reference sample in their collection. The sample was stored at −23 ◦C until further processing.
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3.2. Extraction
The lyophilized animal material was ground and extracted twice with ultrapure water (Milli-Q;
Millipore, Billerica, MA, USA) at 4 ◦C for 24 h in darkness. After centrifugation (4000 rpm at 5 ◦C
for 30 min), the supernatants were pooled and reduced under reduced pressure at 40 ◦C, yielding
24.78 g of aqueous extract. The remaining pellet was freeze-dried and extracted twice with 1:1 v/v
of dichloromethane (Merck, Darmstadt, Germany) and methanol (MeOH; Sigma-Aldrich, Steinheim,
Germany) at 4 ◦C. The combined organic extract was subsequently filtered through a Whatman No. 3
filter paper (Little Chalfont, UK) and concentrated under reduced pressure, affording 5.13 g of organic
extract. Both extracts were stored at −23 ◦C until further use. Aqueous extract was used for isolation
of Securidine A (1), in order to avoid including lower polarity molecules in the purification process.
3.3. Isolation and Purification of Compound 1
An aliquot of the lyophilized aqueous extract (1.5 g) was mixed with 90% MeOH (6–8 mL),
cooled to 4 ◦C, and centrifuged at 4000 rpm and 4 ◦C, in order to precipitate salt. The supernatant
was mixed with 3.0 g resin (Dianon ®HP-20, Supelco Analytical, Bellefonte, PA, USA) and the
mixture was dried by SpeedVac. The dried resin loaded with the aqueous extract was deposited
on top of a column pre-packed with 6.5 g HP20SS, and the extract eluted from the column using a
gradient of H2O/CH3OH/CH3COCH3. The pre-fractionation was performed using a Biotage SP4
chromatography HPFC flash purification system (Biotage, Charlottesville, NA, USA), resulting in
eight fractions. These eight fractions were assayed for cytotoxicity against A2058 melanoma and HT29
colon adenocarcinoma cell lines using the MTS based anticancer assay. Fractions four and five showed
cytotoxic activity and these active fractions were de-replicated using HR-MS. Securidine A (1) was
isolated directly from the aqueous extract by mass guided prep-HPLC.
Isolation of Securidine A (1) was performed by a Waters HPLC purification system. The system
was composed of a 600 pump, a 2996 photodiode array UV detector, a 3100 mass detector and a 2767
sample manager (Milford, MA, USA). The system was controlled with Waters MassLynx version 4.1
and the FractionLynx application manager. The mass of Securidine A (1) (m/z 356.2520) was used as
the collection trigger. The aqueous extract was injected onto a Waters Xterra RP18 (10 mm × 300 mm,
10 µm) HPLC column. Securidine A (1) was eluted with a 10 min with a gradient from 10% to
40% CH3CN (Chromasolv; Sigma-Aldrich) in ultrapure water, both containing 0.1% formic acid
(Pro-analysis, Merck), and the flow rate was 6 mL/min. Further purification was done by Waters
Phenyl-Hexyl Prep (10 mm × 250 mm, 5 µm) HPLC column with a gradient from 10% to 34% of
CH3CN (Chromasolv; Sigma-Aldrich) in ultrapure water with a 10 min and the flow rate of 6 mL/min.
3.4. Structure Determination
UPLC-HR-MS analysis and NMR were used to confirm the structure of Securidine A (1).
UPLC-HR-MS analysis was performed on an Acquity UPLC and a LCT premier Time-of-Fight MS
using ESI+ ionization (Waters). MassLynx version 4.1 was used to process the MS data. The NMR
experiments were acquired on a Bruker Avance III HD spectrometer operating at 599.90 MHz for
protons, equipped with an inverse detected cryo-probe enhanced for 1H, 13C, and 2H. The NMR
samples were prepared by dissolving Securidine A (1) in 500 µL methanol-d3 and transferred into a
5 mm disposable tube. Experiments were typically acquired using gradient selected adiabatic versions
where applicable. All experiments were acquired using Top Spin 3.5 pl2 at 298 K.
3.5. Bioassays
3.5.1. Cytotoxicity
Cell culturing—Human melanoma A2058 (ATCC-CRL-1114 TM, Manassas, VA, USA) and human
colon adenocarcinoma HT29 (ATCC HTB-38 TM) were grown in Dulbecco’s Modified Eagle Medium
(DMEM) (Life technologies TM, city, UK) and Roswell Park Memorial Institute (RPMI)–1640 medium
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(Biochrome GmbH, Germany) respectively. Both media were supplemented with fetal bovine serum
(10%), gentamycin (10 mg/ml), and L-alanyl-L-glutamine (200 mM). Human breast cancer MCF7
(ATCC HTB-22 TM) cells were grown in Eagle’s Minimum Essential Medium (E-MEM) (Biochrom,
GmbH, Berlin, Germany) supplemented with fetal bovine serum (10%), gentamycin (10 mg/mL),
non-essential amino acid without L-alanyl-L-glutamine, sodium pyruvate (100 mM), and sodium
bicarbonate (7.5% w/v). The supplements were purchased from Biochem, GmbH, Berlin, Germany.
All cells were incubated at 37 ◦C with 5% CO2 and 95% air. Cells were sub-cultured with fresh
medium every three to four days. The test concentrations (50 µM and 100 µM) were prepared from the
stock solution of pure compound (10 mg/mL in 100% DMSO) which is dissolved in supplemented
RPMI-1640 medium.
Cell viability was tested against three adherent cancer cell lines, human melanoma A2058,
human colon adenocarcinoma HT29, and human breast cancer MCF7 cell lines in vitro, using an MTS
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt]
colorimetric method. The growing cells were suspended in 100 µL of supplemented medium seeded
at a density of 2000 cells/well in a 96-well microtiter plates (Nunclon TM Delta Surface, Thermo Fisher
Scientific, Denmark). The cells were incubated at 37 ◦C for 24 h. After removal of old medium, the cells
were treated with 50 µM and 100 µM of Securidine A (1). After 72 h incubation, 10 µL of Cell titer 96 ®
Aqueous One Solution Reagent (Promega, Madison, WI, USA) was added to each well and the plates
were incubated for 1 h. The absorbance readings at 485 nm was measured using DTX 880 multimode
detector (Beckman coulter, CA, USA). Cells with RPMI-1640 medium were used as negative control
and cells treated with Triton® X-100 (Sigma-Aldrich, Steinheim, Germany) as positive control. Growth
inhibition was measured by optical density (OD) and was calculated as: Cell survival (%) = (Average
of parallels − positive control)/(negative control − positive control) × 100
3.5.2. Antibacterial Assay
Test strains and culture media—The antibacterial activity of Securidine A (1) was determined
by using a minimum inhibitory concentration (MIC) assay against Staphylococcus aureus (ATCC
25923), Escherichia coli (ATCC 25922), Enterococcus faecalis (ATCC 29212), Pseudomonas aeruginosa (ATCC
27853), and Streptococcus agalactiae (ATCC 12386). Antibacterial test was performed in sterile Muller
Hinton broth (Becton Dickinson, Sparks, MD, USA) and brain heart infusion broth (Becton Dickinson).
The bacterial cultures were obtained from the stock (−80 ◦C) and were grown on blood agar (acquired
from the University hospital, UiT, Tromsø, Norway) at 37 ◦C for 24 h and working bacterial stock culture
were maintained at 4 ◦C. An overnight culture of each strain was prepared and 2 mL of overnight
culture was inoculated in 25 mL of growth media and incubated at 37 ◦C on the shaker at 180 rpm,
until the culture reaches the turbidity according to 0.5 McFarland standard (1.0 × 108 colony forming
unit (CFU)/mL). In this study, bacterial cultures were diluted in 1:100 and then 1:10 in growth media
and the final concentration of bacterial cells in the wells were adjusted to 0.5–3.0 × 105 (CFU)/mL
of S. aureus, E. coli, E. faecalis, and Streptococcus agalactiae and 3.0–7.0 × 104 CFU/mL of P. aeruginosa.
Test concentrations (50 µM and 100 µM) were prepared from the stock solution of Securidine A (1)
(10 mg/mL in 100% DMSO), and was dissolved in MilliQ water.
From the test concentrations, 50 µL was transferred into a 96-well microtiter plate (NunclonTM
Delta Surface, Thermo Fisher Scientific, Denmark). Subsequently, 50 µL of final concentration of
bacterial cells were added and incubated at 37 ◦C for 24 h. After incubation, the activity was measured
as absorbance at 600 nm in a plate reader (1420 Victor3 TM multilabel counter, PerkinElmer®, Singapore)
and WorkOut 2.0 software (Dazdaq Ltd, Brighton, UK) was used for plate reading. Bacterial suspension
with MilliQ water was used as positive control and growth medium with MilliQ water as negative
control. Gentamycin (Amresco, OH, USA) was used as the reference control of this assay. The inhibition
was evaluated by the average of parallel OD value. The OD value ≤0.05 considered as active and
≥0.09 was considered inactive.
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3.5.3. Protein Tyrosine Phosphatase 1B Assay
Reagents—(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES; Sigma-Aldrich,
Steinheim, Germany), sodium chloride (NaCl; Sigma-Aldrich), dithiothreitol (Sigma-Aldrich),
ethylene diamine tetra-acetic acid disodium salt dehydrate (EDTA; Sigma-Aldrich), bovine
serum albumin (Sigma Aldrich), human recombinant protein tyrosine phosphatase 1B enzyme
(PTP1B; Merck-Calbiochem, Darmstadt, Germany), protein tyrosine phosphatase inhibitor IV
(Merck-Calbiochem), 6,8-difluoro-4-methylumbelliferylphosphate (DiFMUP; VWR, Leuven, Belgium).
The test concentration (10 µM and 50 µM) was obtained from stock solution (10 mg/mL in 100%
DMSO) of Securidine A (1) and was dissolved in the assay buffer.
PTP1B activity of Securidine A (1) was measured in the presence of human recombinant PTP1B
enzyme, flurogenic substrate DiFMUP, and the buffer solution in black polystyrene 96-well microtiter
plate (FluoroNuncTM MaxiSorp Surface, Capital Scientific, TX, USA). The final volume of the mixture
was 100 µL in each well. Each well contained 25 µL of buffer solution (pH 7.2) (25 mM HEPES, 50 mM
NaCl, 2 mM dithiothreitol, 2.5 mM EDTA and 0.01 mg/mL bovine serum albumin), 25 µL of Securidine
A (1), and 50 µL of PTP1B enzyme (31.2 ng/mL). Then, the plate was incubated at 37 ◦C. After 30 min
incubation, 25 µL of 10 µM fluorogenic substrate DiFMUP was added into wells and incubated again
at 37 ◦C for 10 min. The inhibition of enzyme activity was measured as the intensity of fluorescence at
360 nm excitation and 465 nm emission wavelengths by using DTX 880 Multimode detector (Beckman
coulter, CA, USA). The assay buffer was used as the positive control and protein tyrosine inhibitor
IV (160 µM) was used as the negative control. The inhibition of enzyme activity was measured from
the fluorescence and calculated with positive and negative control. The inhibition of enzyme activity
was expressed in percentage and the activity lower than 30% was considered active. The inhibition
of enzyme activity was calculated by (Average of triplicates − negative control)/(positive control −
negative control) × 100.
3.5.4. Biofilm Assay
Test strains—The test strains Staphylococcus epidermidis (RP62A-42-77 ATCC-35984) and
Staphylococcus haemolyticus (Clinical isolate 8-7A) from the stock were grown on blood agar (acquired
from University hospital, UiT, Tromsø) at 37 ◦C for 24 h and these working bacterial stock were
maintained at 4 ◦C.
The bacterial strain S. epidermidis was used to test the biofilm formation on the polystyrene
96-well microtiter plate (Nunclon TM Delta Surface, 734-2097, Thermo Fisher Scientific, Denmark).
The overnight culture was grown in 5 mL of sterile tryptic soy broth (TSB; Merck, Darmstadt, Germany)
in a shaking incubator at 37 ◦C and diluted in 1:100 in TSB medium with 1% of glucose (Sigma-Aldrich).
Securidine A (1) from the stock (10 mg/mL) was dissolved in the MilliQ water, to prepare 100 µM test
concentration. From the test concentration, 50 µL was transferred into the wells, subsequently the
diluted test strain 50 µL was added and incubated at 37 ◦C for overnight. S. epidermidis with sterile
MilliQ water was used as positive, S. haemolyticus with sterile MilliQ water was used as negative
control and medium, with sterile MilliQ water used as blank.
The biofilm formation in the well was determined by using crystal violet (Merck) staining.
The bacterial suspension was removed carefully on the cell paper and the plate was gently washed
with tap water two or three times. After the biofilm fixation was done at 65 ◦C for 1 h, the cells were
stained with 70 µL 0.1% of crystal violet. After 10 min incubation, the crystal violet was removed
carefully on the cell paper and the plate was washed with tap water two or three times. The plate was
dried at 65 ◦C for 1 h and 70 µL 70% ethanol (VWR) was added into the wells. Thereafter, the microtiter
plate was placed on a shaker for 5–10 min. The inhibition of biofilm was assessed by using in the
Victor3 TM multilabel counter at 600 nm and measuring the optical density (OD). If the inhibition of
biofilm rate was 0.25 or lower the OD value was considered active.
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4. Conclusions
The new brominated tyrosine derivative Securidine A (1) was isolated from the aqueous extract
of the marine bryozoan Securiflustra securifrons. The structure was determined by interpretation of data
from 1D and 2D NMR experiments and mass spectrometry analysis. In this study, Securidine A (1) did
not show any significant biological activities in the applied bioassays. Further bioactivity profiling is
required in order to identify any potential biological activities of the molecule.
Supplementary Materials: Supplementary data S1–S6 (1H, 13C, HSQC, HMBC, H2BC, COSY and ROESY NMR
spectral data of isolated compound) associated with this article can be found online.
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Abstract: One fraction from the organic extract of the Arctic marine bryozoan Securiflustra securifrons 14 
was found to be active against the human pathogenic bacterium Streptococcus agalactiae (gr. B). 15 
Chemical investigation of the fraction revealed that it contained several variants of the previously 16 
reported securamines and securidine A (6). The securamines are highly modified hexacyclic 17 
alkaloids sharing a common isoprene-histamine-tryptamine backbone. Compound 6 is a 18 
brominated tyrosine derivative. In this study, we describe the antimicrobial activities of securamine 19 
C, E and H – J (4, 5 and 1 – 3) and the attempt to deconvolute the mode of action of 1 using modified 20 
variants of Bacillus subtilis and Escherichia coli. 21 
Keywords: Marine bryozoan; Securiflustra securifrons; the securamines; antimicrobial activity; 22 
marine bioprospecting 23 
 24 
1. Introduction 25 
The increasing prevalence of antibiotic resistant bacteria is recognized as one of the most serious 26 
global threats to human health in the 21st century. Extensive use of antibiotics together with declining 27 
investments into discovery and development of new treatment options to combat pathogens have 28 
aggravated the problem [1, 2]. In the search for new antimicrobial agents, nature remains the richest 29 
and most versatile source [3, 4]. In fact, close to 80% of all marketed anti-infective agents originates 30 
from a natural source [5]. Bryozoans are a phylum of suspension-feeding mainly colonial 31 
invertebrates found in aquatic benthic ecosystems throughout the world [6]. They generally form 32 
sessile colonies of genetically identical, polymorphic units termed zooids [7, 8]. These colonies are 33 
extremely vulnerable to biofouling, predation by grazers and pathogenic attacks [9, 10]. As a result, 34 
bryozoan biomass has yielded several structurally diverse bioactive secondary metabolites. In 35 
general, little is known regarding the ecological role of bryozoan derived secondary metabolites. 36 
These compounds are attractive starting points for pharmaceutical development. The best known 37 
examples are the bryostatins, isolated from Bugula neritina (Linnaeus, 1758), some of which are under 38 
clinical development as an anticancer drug candidate for combination therapy [11] and neurological 39 
disorders [12-14]. In addition, several compounds with antimicrobial properties, including inhibition 40 
of Gram-negative (G-) and Gram-positive (G+) bacteria and quorum-sensing [15] and fungicidal 41 
properties [16], have been isolated. These include the flustramines, brominated tricyclic indole 42 
alkaloids isolated from Flustra foliacea (Linnaeus, 1758) [17, 18],the tribrominated indole 43 
terminoflustrindole A isolated from Terminoflustra (Chartella) membranaceotruncata (Smitt, 1868) [16, 44 
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19], the pterocellins isolated from Pterocella vesiculosa (Lamarck, 1816)[20] and the alternatamides 45 
isolated from Amathia alternata (Lamouroux, 1816)[21] 46 
As part of our search for bioactive secondary metabolites from marine organisms we have 47 
previously prepared the aqueous and organic extracts of Securiflustra securifrons (Pallas, 1766) into 48 
eight fractions each using RP-flash chromatography and tested them for anticancer activity [22, 23]. 49 
Out of these, fraction five of the organic extract was found to be active against a human melanoma 50 
cancer cell line. The components in this fraction found to be responsible for the cytotoxicity were the 51 
hexacyclic alkaloids securamine C (4), E (5) and H – J (1 – 3) (Figure 1). The structures and cytotoxic 52 
properties of 1 - 5 have been reported by our group [22]. Furthermore, our group has reported the 53 
structure and bioactivity characterization of securidine A (6) (Figure 1), isolated from the aqueous 54 
extract [23].  55 
In this study, fraction three of the organic extract of S. securifrons was found to be active against 56 
the pathogenic bacterium Streptococcus agalactiae (Gr. B). HRMS analysis of this fraction revealed the 57 
presence of securamines and 6. Compound 6 has been determined inactive against microorganisms 58 
[23]. The antibacterial properties of the securamines have however not been previously examined. 59 
This, coupled with the knowledge that nature has provided a wealth of promising lead structures for 60 
antibiotic development [24-26], motivated an investigation into the potential of the securamines as 61 
antibiotics. Compounds 1, 2 and 5 were found to inhibit the growth of G+ bacteria, out of which 1 62 
was the most active with minimum inhibitory concentration (MIC) values as low as 3.13 µM. 63 
Compound 1 was therefore selected for mode of action studies towards modified variants of the G+ 64 
bacterium Bacillus subtilis and the G- bacterium E. coli. While E. coli was not affected, these studies 65 
revealed that 1 did not affect B. subtilis viability by bacterial membrane integrity disruption at 66 
concentrations close to the MIC. Furthermore, 1 was found to reduce metabolic activity of B. subtilis, 67 
indicating that the compound affected B. subtilis viability by interacting with an intracellular target 68 
which is part of the metabolic machinery of the bacterium. Therefore, 1 was assayed in a mode of 69 
action screening against reporter gene based bacterial biosensors for its potential to interfere with 70 
DNA replication, transcription, translation, fatty acid- and folic acid synthesis. Our results did not 71 
indicate that any of these bacterial processes were affected by 1, although such activity could not be 72 
excluded, since the assay only detect a selected range of known activities in one model organism. 73 
Furthermore, 1 and 6 were assayed together against bacteria to evaluate whether their co-exposure 74 
produced synergistic effect against the assayed strains. Our study revealed no such effect. The effect 75 
of 1 on the metabolic activity of B. subtilis however demonstrates the potential of the compound as a 76 




Figure 1. Structures of securamine C, E and H – J (4, 5 and 1 – 3) and securidine A (6), isolated from 81 
extracts of the Arctic marine bryozoan Securiflustra securifrons.  82 
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2. Results and discussion 83 
2.1. Biomass, extraction, fractionation, compound isolation and structure elucidation 84 
The biomass of S. securifrons was collected off the coast of Hjelmsøya, freeze dried and subjected 85 
to liquid-liquid extraction and fractionated using flash chromatography. Compounds 1 – 6 were 86 
isolated using mass guided semi-preparative HPLC and their structures elucidated using 87 
spectroscopic methods (HRMS, 1D- and 2D-MNR) as previously described [22, 23].  88 
2.2. Antibacterial screening and chemical investigation of the flash fractions of S. securifrons 89 
The flash fractions of the organic S. securifrons extract were assayed for activity against the 90 
pathogenic bacteria strains S. aureus, E. faecalis, E. coli, P. aeruginosa and S. agalactiae (Gr. B) at 250 91 
µg/mL. Flash fraction three (eluting at 50% MeOH) was found to be active against the G+ bacteria S. 92 
agalactiae (Gr. B). Fraction three was inactive against the remaining bacteria and the remaining 93 
fractions were inactive against all bacteria. Chemical analysis of the fraction using UHPLC-HRMS 94 
revealed that it contained compounds belonging to the securamine family, including compounds 1, 95 
2, 4 and 5. In addition, the brominated tyrosine derivative 6 was present in abundant amounts (Figure 96 
2). As 6 has previously been tested for antibacterial activity, resulting to be inactive [23], only the 97 
securamines were selected for antibacterial bioactivity testing.  98 
 99 
 100 
Figure 2. The base peak intensity chromatogram of flash fraction three of the organic extract of S. 101 
securifrons showed the presence of securidine A (6) and several securamines, including securamine H, 102 
I, C and E (1, 2, 4 and 5). 103 
2.3. Antimicrobial activity of 1 - 5 104 
The MIC of compounds 1 – 5 against four G+ and two G- bacteria strains, three yeast strains and 105 
towards the biofilm formation capability of Staphylococcus epidermidis were tested (Table 1). 106 
Compounds 1, 2 and 5 showed activity against all or most of the G+ strains. No activity was found 107 
towards the G- bacteria, the yeast strains or against biofilm formation at the highest assay 108 
concentration (50 µM). Compared to flash fraction three, the purified securamines show a wider 109 
range of antibacterial activity. The discrepancy in bioactivity between fraction three and the 110 
securamines can be explained by several phenomena. The fraction is a complex mixture of natural 111 
products, where the antibacterial securamines only constitute a small part. Thus, despite the 112 
relatively high assay concentration of 250 µg/mL, the purified compounds were most likely tested at 113 
lower concentrations when assayed as part of flash fraction three, compared to when they were 114 
assayed in their pure form. Moreover, securamine bioactivities may be masked by other sample 115 
components present in flash fraction three, which may affect their solubility or interact more potently 116 
with the securamines compared to their target on or in the bacteria [27]. Furthermore, 1 was found in 117 
abundant amounts in flash fraction five of the organic extract of S. securifrons. This fraction did not 118 
have antibacterial activity at 250 µg/mL, as previously described [22]. This difference can be 119 
explained by the same reasons as mentioned above. 120 
Based on these results it appears that a double bond in the D-ring between C-2 and C-3 and more 121 
than one bromine on the A-ring at C-16, C-17 and/or C-18 are important for the antibacterial activity 122 
of the securamines. This observed structure activity relationship (SAR) correlates well with the 123 
previously reported SAR of the securamines against melanoma, lung and breast cancer cell lines [22], 124 
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where 1, 2, 4 and 5 inhibited cell viability. The lowest IC50 value, 1.4 µM, was measured for 1 against 125 
a human melanoma cell line. Compound 1 is brominated on C-16, C-17 and C-18 and have a double 126 
bond between C-2 and C-3. This may further indicate that the activities of the securamines against 127 
both bacteria and cancer cell lines are caused by an unspecific interaction with and disruption of 128 
biological membrane integrity. This is however unlikely, as the herein assayed yeast strains were 129 
unaffected by the securamines at the highest assayed concentration (50 µM), indicating an unrelated 130 
intracellular target in the cancer cells and bacteria. Compound 1 showed the broadest and most 131 
potent inhibition, with MIC values ranging from 3.13 – 6.25 µM against the G+ bacteria, and was 132 
therefore chosen for further investigation . 133 
Table 1. MIC (µM) of securamine H-J, C and E (1 – 5) against four G+ and two G- bacteria strains, 134 
against Staphylococcus epidermidis biofilm formation and against three yeast strains. 135 
Microorganisms 
Minimum inhibitory concentration (µM) 
1 2 3 4 5 
G+ bacteria:      
Bacillus subtilis 6.25 >50 >50 >50 >50 
Staphylococcus aureus 3.13 12.5 >50 >50 25 
Enterococcus faecalis 6.25 25 >50 >50 50 
Streptococcus agalactiae (Gr. B) 6.25 25 >50 >50 25 
G- bacteria:      
Escherichia coli >50 >50 >50 >50 >50 
Pseudomonas aeruginosa >50 >50 >50 >50 >50 
Biofilm formation      
Staphylococcus epidermidis >50 >50 >50 >50 >50 
Yeast      
Candida albicans >50 >50 >50 >50 >50 
Rhodotorula sp. >50 >50 >50 >50 >50 
Aureobasidium pullulans >50 >50 >50 >50 >50 
2.4. Real-time measurement of membrane integrity of bacteria when exposed to 1 136 
B. subtilis and E. coli, carrying the pCSS962 plasmid with the LucGR gene, were used to assess 137 
the membrane disruptive properties of 1. The strains express eukaryotic luciferase and will emit 138 
luminescence if its membrane is disrupted and D-luciferin from the growth medium is allowed to 139 
diffuse into the cell [28]. If the bacteria cells die following membrane disruption, an initial rise in 140 
relative luminescence units (RLU) caused by D-luciferin influx, will be followed by declining RLU 141 
values as bacterial ATP reserves are exhausted and the enzymatic reaction consequently stopped. 142 
The luminescence measurements of B. subtilis and E. coli after exposure to ranging concentrations of 143 
1 or chlorhexidine (CHX, positive control), an antibiotic known for its cell wall and membrane-144 
disruptive activities [29], can be seen in Figure 3. CHX treated B. subtilis gave an initial increase 145 
followed by a decrease in RLU values. In contrast to this, 1 caused a persistent increase in light 146 
emission from the cells within the 3 min assay time at the three highest concentrations tested (12.5, 147 
25 and 50 µM; 2, 4 and 8 x the MIC value of 6.25 µM, respectively). This increase were most likely 148 
caused by an increased D-luciferin influx into the cells caused by effects on the membrane. This effect 149 
does however not appear to affect the viability of B. subtilis, as the ATP reserves in the bacteria are 150 
not exhausted and resultantly no delayed drop in RLU was observed, indicating that the effect of 1 151 
was different from that of CHX. The lack of a drop in ATP reserves following B. subtilis exposure to 152 
1 furthermore indicates that 1 is bacteriostatic rather than bactericidal at the highest assayed 153 
concentrations. At 6.25 µM (and at lower concentrations, data not shown) 1 did not cause an influx 154 
of D-luciferin, as relative light emission remained equal to the water control. In contrast to CHX, no 155 
substantially increase in D-luciferin uptake and thus no affect plasma membrane integrity of E. coli 156 
could be detected for 1, even at the highest assayed concentrations (Figure 3B). 157 
 158 
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Figure 3. Kinetics of the relative luminescence emission by A) B. subtilis (pCSS962) and B) E. coli 160 
(pCSS962) treated with ranging concentrations of securamine H (1) or chlorhexidine (CHX) (in green 161 
and blue colors, respectively). Each point is the mean of three independent measurements. CHX and 162 
water (red color) were used as positive and negative controls, respectively. 163 
2.5. Assesment of membrane potential of bacteria when exposed to 1 164 
To further elucidate if 1 affected the membrane integrity of B. subtilis directly, the membrane 165 
potential of B. subtilis was measured after 3 min exposure to ranging concentrations of 1. Bacterial 166 
cells were stained with a membrane potential sensitive dye and subsequently analyzed by flow 167 
cytometry. The assay is based on the use of 3,3’-diethylcarbocyanine iodide (DiOC2(3)), whose 168 
fluorescence shifts from green to red in response to higher cytosolic concentrations in cells with active 169 
membrane potential where the dye aggregates. Ratiometric analysis of green to red fluorescence 170 
allows for estimating changes in membrane potential of bacteria [30]. CHX and carbonyl cyanide m-171 
chlorophenylhydrazone (CCCP) were used as positive and negative controls, respectively. CCCP 172 
blocks the generation of the electrochemical proton gradient, and thus lowers the membrane potential 173 
in bacteria [31]. Increasing concentrations of CHX decreased the ratio of red/green, showing that a 174 
higher CHX concentrations result in higher fraction of bacteria with disrupted membranes. For 1, 175 
increased concentrations resulted in a decreased red/green ratio, however this decrease was 176 
significantly less marked compared to the CCCP and CHX controls. At the observed MIC (6.25 µM), 177 
only a slight shift were visible, further indicating that the activity of 1 were not due to direct 178 




Figure 4. The effect of securamine H (1) in comparison to chlorhexidine (CHX) on the membrane 183 
potential of B. subtilis. The bacteria were treated for 3 min with ranging concentrations of 1 or CHX 184 
and subsequently incubated for at least 30 min with 30 µM DiSO2(3). The overlaid historgrams show 185 
the positive and the negative controls treated with 5 µM carbonyl cyanide m-chlorophenylhydrazone 186 
(CCCP) (shaded dark grey) and water (shaded light grey), respectively. Measurements depicting 187 
analysis of 1 are shown as red lines and CHX as blue lines. The ratiometric values (red/green) are 188 
depicted on the x axis, the relative number of events on the y axis. 189 
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2.6. Effect of 1 on cell viability measured in real-time 190 
B. subtilis carrying a chromosomal integration of a luxABCDE [32] operon and E. coli carrying 191 
the pCGLS-11 [33] plasmid with a Photorhabdus luminescens lux operon (luxCDABE) were used to 192 
assess the effect of 1 on bacterial cell viability measured in real-time. From these operons the strains 193 
express a bacterial luciferase and fatty acid reductases for regeneration of long-chain fatty aldehydes, 194 
which serve as substrates for light production. Light production is therefore linked to several 195 
metabolic processes, which in turn depend on the regeneration of reduction equivalents and ATP [34, 196 
35]. While light production indicates active metabolism, loss of light production indicates a decrease 197 
in metabolic activity, and hence, reduced viability of the cells. The measured luminescence of B. 198 
subtilis and E. coli after addition ranging concentrations of 1 or CHX can be seen in Figure 5. At 199 
concentrations above the MIC (6.25 μM) 1 affected the viability of B. subtilis within the 3 min assay 200 
time (Figure 5A). Indeed, 1 at a concentration of 50 μM affected cell viability of the strain at a similar 201 
level as CHX at 3.1 µM, resulting in a decrease of around 40% of relative luminescence units after 3 202 
min. The decrease in light emission within 3 min at concentrations above the MIC confirmed that cell 203 
viability was affected relatively fast. However, even at concentrations above the MIC viability does 204 
not drop below 50%, which was the case for CHX. In addition, the ATP dependent membrane assay 205 
showed elevated light emission at these concentrations indicating that ATP levels are not the limiting 206 




Figure 5. Kinetics of the relative luminescence emission by A) B. subtilis (pCGLS-11) and B) E. coli 211 
(pCGLS-11) treated with ranging concentrations of securamine H (1) or chlorhexidine (CHX). Each 212 
point is the mean of three independent measurements. 213 
In summary, the results from the membrane integrity and metabolic activity assays show an 214 
influx of D-luciferin at concentrations higher than the MIC, no effect on membrane potential and 215 
reduction of metabolic activity in B. subtilis exposed to 1. The effect of 1 on B. subtilis viability is thus 216 
most likely not caused by direct effects on the cell membrane, but rather by interference with one or 217 
more metabolic processes in B. subtilis.   218 
2.7. Investigation of possible intracellular targets of 1 typical for conventional antibiotics  219 
In an attempt to gather further information about the mode of action of 1, the compound was 220 
tested against a panel of six biosensors responding to interference with some major metabolic 221 
pathways in B. subtilis. Compound 1 was tested for interference with DNA replication, transcription, 222 
translation as well as interference with fatty acid, cell wall and folic acid synthesis. Antibiotics of the 223 
respective modes of action, as shown in Table 3, served as positive controls. None of the strains used 224 
reacted to coincubation with 1 at the assayed concentrations during the 8 h the assay was run (twofold 225 
dilution series between 50 and 0.39 µM). The purpose of the sensors is to detect similar activity, but 226 
negative results do not exclude a given mode of action. While for example erythromycin efficiently 227 
induces the sensor for translation interference, kanamycin does not [36]. Similarly, the cell envelope 228 
stress sensor, which is based on the liaI promoter and the liaRS two component system, is most 229 
sensitive when challenged with antibiotics affecting the lipidII cycle, as is the case for bacitracin or 230 
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vancomycin, while they remain uninduced by penicillin [37]. This hampers the interpretation of the 231 
results since all the assays for the activity of 1 were negative. However, 1 seems not to belong to the 232 
subgroups of antibiotic mode of actions the sensors recognize. Interestingly, the liaI based cell 233 
envelope stress sensor is known to respond to membrane active compounds such as Nisin [37]. 234 
Therefore the negative response to 1 was in accordance with the earlier results indicating a different 235 
mode of action than interference with membrane integrity.  236 
Table 3. List of sensor strains with the promoter region fused to the luxABCDE operon located in the 237 
sacA region of the B. subtilis 168 chromosome. Assays were started with bacteria at mid log phase 238 
diluted to approximately 107 bacteria. The respective positive control antibiotics used are shown in 239 
the last column. 240 
2.8. Synergistic antibacterial effects of 1 and 6 241 
When tested alone, 6 was found to not be active against bacteria and biofilm formation at 100 242 
µM [23]. To evaluate whether a combination of compounds from fraction three of the organic extract 243 
of S. securifrons could potentiate each other’s antibacterial activity, 1 and 6 were assayed as a mixture 244 
at ranging concentrations arranged in a checkerboard titration (assay concentrations of both 245 
compounds: 50 to 1.56 µM, 6 concentration points, 2 fold dilution). Compound 6 was chosen to be 246 
tested together with 1 over the other securamine variants as the securamines are present together in 247 
substantially higher concentrations in flash fractions four, five and six of the organic extract of S. 248 
securifrons, and these fractions were not active in the antibacterial screening. This indicates that a 249 
mixture of securamines does not potentiate each other’s antibacterial activities in these specific 250 
fractions. The combination of 6 and the securamines however only occurs in fraction three or the 251 
organic extract of S. securifrons. The various mixtures of 1 and 6 were tested for synergistic activity 252 
against S. aureus, E. faecalis, E. coli, P. aeruginosa and S. agalactiae (Gr. B). The G- strains were not 253 
affected by the mixture. The MIC values of 1 against the G+ strains in a mixture with 6 were identical 254 
to those measured for 1 alone (Table 1: S. aureus: 3.13 µM, E. faecalis: 6.25 µM, S. agalactiae (Gr. B): 6.25 255 
µM). The ecological function and bioactivity of 6 thus still remains to be determined.  256 
3. Experimental section  257 
3.1. Animal material, extraction, fractionation, compound isolation and structure elucidation 258 
Specimens of S. securifrons were collected off the coast of Hjelmsøya, Norway in 2014 using an 259 
Agassi’s dredge trawl at 72 m depth. The specimens were prepared into an organic extract, which 260 
was further fractionated into eight fractions using RP-flash chromatography and tested for 261 
bioactivity. The compounds were isolated using mass-guided semi-preparative HPLC and their 262 
structure elucidated using spectroscopic methods (HRMS, 1D- and 2D-NMR), all as previously 263 
described in detail [22, 23]. 264 
  265 
Strain number Target Promoter Control antibiotic 
EM10 DNA replication yorB Ciprofloxacin 
EM11 Transcription helD Rifampicin 
EM12 Translation yheI Erythromycin 
HMB67 Cell envelope liaI Vancomycin 
HMB69 Fatty acid synthesis fabHB Irgasan 
HMB70 Folic acid synthesis panB Trimethoprim 
HMB62 Constitutive control veg - 
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3.2. Microorganism strains, growth media and assay temperature 266 
Enterococcus faecalis (ATCC: 29212) and Streptococcus agalactiae (Gr. B) (ATCC: 12386) were grown 267 
and assayed in brain-heart infusion broth (BHI; Oxoid, Hampshire, England). Staphylococcus aureus 268 
(ATCC: 25923), Escherichia coli (ATCC: 25922), Pseudomonas aeruginosa (ATCC: 27853) and Bacillus 269 
subtilis (ATCC: 23857) and its derivatives were grown on Mueller Hinton Broth (MH; Merck, 270 
Darmstad, Germany). Staphylococcus epidermidis (ATCC: 35984) was grown and assayed in tryptic soy 271 
broth (TS; Merck, Darmstadt, Germany). All bacteria were grown and assayed at 37 °C. The yeast 272 
strains Candida albicans (ATCC: 10231) and Rhodotorula sp. and the Aureobasidium pollulans mold 273 
(Rhodotorula sp and A. pollulans were obtained from Professor Arne Tronsmo, The Norwegian College 274 
of Life Sciences, Ås, Norway), were cultivated on potato dextrose (PD) agar (Difco, Detroit, MI, USA) 275 
with 2% D(+)-glucose (Merck, Darmstad, Germany) at room temperature. 276 
3.3. Antimicrobial and anti biofilm formation assays 277 
3.3.1. Antibacterial assay 278 
MIC values of 1 – 5 were determined using the broth microdilution method, as previously 279 
described [23]. Briefly, suspended bacteria in log phase were added to 96-well microtiterplates at a 280 
concentration of 1.500 – 15.000 colony forming units/mL. Serial dilutions of 1 – 5 were subsequently 281 
added and left to inoculate for 24 h before growth inhibition was measured using a Victor multilabel 282 
counter (PerkinElmer, Singapore) at 600 nm. Growth medium diluted with water (1:1) was used as 283 
negative control and bacteria suspension diluted with water (1:1) as positive control. For B. subtilis, 284 
oxytetracycline was used as positive assay control, for the remaining strains, gentamycin was used. 285 
The assays were repeated three times.  286 
3.3.2. Inhibition of biofilm formation 287 
S. epidermidis was used to assess the effect of 1 – 5 on biofilm formation. An overnight culture of 288 
S. epidermidis was diluted with fresh TS broth with 1% glucose (1:100), transferred to the wells of 96-289 
well microtiter plates and added ranging concentrations (assay cons: 50 – 0.39 µM) of 1 – 5. After 290 
overnight incubation, the bacteria suspension was carefully discarded, the biofilm fixed by 291 
incubation at 55 °C for 1h and stained by 0.1% crystal violet for 5 min before being washed away with 292 
water. The plates were once more left to dry at 55 °C for 1h before 70 µL 70% ethanol was added to 293 
each well and the plates left to incubate for 10 min before biofilm formation was observed by visual 294 
inspection of the plates. The MIC was defined as the lowest concentration where no biofilm formation 295 
was visible. S. epidermidis suspension, diluted with 50 μL of water, was used as a positive control, and 296 
50 μL Staphylococcus haemolyticus suspension with 50 μL of water as negative control. A mixture of 50 297 
μL water and 50 μL TS broth was used as assay control.  298 
3.3.3. Antifungal assay 299 
Fungal spores of yeast strains Candida albicans and Rhodotorula sp. and the A. pollulans mold, 300 
were dissolved in PD broth and the cell concentration was determined and adjusted after counting 301 
in a Bürker chamber. A final fungal spore concentration of 2 × 105 spores/mL were inoculated in 96-302 
well nunc microtiter plates (100 µL total well volume) along with ranging concentrations of 1 – 5 (50 303 
– 0.78 µM). The assay plates were incubated in room temperature for 24 h (C. albicans) and 48 h (A. 304 
pollulans and Rhodotorula sp.). Ranging concentrations of amphotericin-B was used as positive control 305 
(32 - 0.25 µg/mL), and water as a negative (growth) control. After incubation the OD value (600 nm) 306 
was measured in a Synergy H1 Hybrid Reader (BioTek, Winooski, VT, USA). MIC values of 1 – 5 307 
were defined as the lowest concentration of the compounds that showed >90% inhibition compared 308 
to the negative growth control (as measured by OD). The assays were repeated three times.   309 
  310 
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3.4. Mode of action studies 311 
3.4.1. Real-time membrane integrity assay measuring immediate membrane disruption 312 
The real-time membrane integrity assay was performed using B. subtilis 168 and E. coli K12 313 
(MC1061), both carrying the plasmid pCSS962 with the eukaryotic luciferase gene lucGR. Luciferase 314 
is dependent on D-luciferin as substrate to emit light, a substrate that does not penetrate intact cell 315 
membranes. The assay is a modification of a previously described protocol [28]. B. subtilis and E. coli 316 
were cultured overnight in MH broth with 5 µg/mL chloramphenicol (Merck KGaA, Darmstad, 317 
Germany) and a mixture of 20 μg/mL chloramphenicol/100μg/mL ampicillin, respectively, before 318 
being centrifuged at 4500 rpm for 10 min. The supernatant was removed and the pellet resuspended 319 
in MH broth to give an OD600 of 0.1. D-luciferin potassium salt (assay concentration: 1 mM) was added 320 
and background luminescence measured. Ranging concentrations of 1 (assay concentrations: 50 – 321 
0.78 µM) dissolved in water were added to black round-bottom 96-well microtiterplates (Nunc, 322 
Roskilde, Denmark) as well as a ranging concentrations of the control, CHX acetate (assay 323 
concentrations 50 µM – 1.6 µM). The plates were placed in a Synergy H1 Hybrid Reader (BioTek, 324 
Winooski, VT, USA). Aliquots (90 µL, to give a total assay volume of 100 µL) of the prepared bacteria 325 
suspension was added to the test wells by an automatic injector with tracking of the luminescence 326 
emission every second for 180 s. Three independent measurements were conducted. 327 
3.4.2. Membrane potential assay 328 
To analyse the effects of 1 on the membrane potential of Bacillus subtilis 168, the BacLight 329 
bacterial membrane potential kit (Invitrogen) was used. The assays were performed in 96 well 1.8 ml 330 
deepwell-plates (Corning) and analyzed by a Cube8 flowcytometer with an autosampler (Sysmex). 331 
The assay is based on the dye DiOC2(3), which causes green fluorescens in all bacterial cells. The 332 
fluorescense shifts to red when the dye molecules self associate due to their accumulation in the 333 
cytoplasm of viable bacteria with intact membrane potential [30]. Differences in fluorescence 334 
emission were detected by flowcytometry. The ratiometric values of red/green fluorescence were 335 
used to analyze if the proton gradient of the tested cells were affected or not. The experiment was 336 
performed according to the manufacturers suggestions but adapted to the 96 well format and 337 
therefore conducted with reduced volumes. Briefly, 5 µl 3mM DiOC2(3) solution was added to 500 338 
µl cell suspension, which contained approximately 106 bacteria and had been pretreated for 3 min 339 
with different concentrations of the respective analytes. Before starting the measurement the samples 340 
were incubated in the dark for 30 min at RT. The samples were then measured in the Cube8 and 341 
analyzed with excitation by the blue laser (488 nm) and forwards scatter (FSC), side scatter (SSC), FL1 342 
(emission 536/40 nm) and FL3 (emission 675/20 nm). Data analysis was performed by the freely 343 
available flowing software using the first 2000 events of the bacterial population in each measurement 344 
for ratiometric analysis (flowingsoftware.btk.fi). 345 
3.4.3. Real-time cell viability assay 346 
The real-time cell viability assay was performed using B. subtilis 168 (ATCC: 23857) and E. coli 347 
K12 (ATCC: MC1061) carrying a chromosomal integration of the luxABCDE operon or the plasmid 348 
pCGLS-11 with the lux operon luxCDABE, respectively. The assay is a modification of a previously 349 
described protocol [38]. B subtilis and E. coli were cultured overnight in MH broth with 5 µg/mL 350 
chloramphenicol (Merck KGaA, Darmstad, Germany) and 100 μg/mL ampicillin, respectively, before 351 
being centrifuged at 4500 rpm for 10 min. The supernatant was removed and the pellet resuspended 352 
in MH broth to give an OD600 of 0.1. Ranging concentrations of 1 (assay concentrations: 50 – 0.78 µM) 353 
dissolved in water were added to black round-bottom 96-well microtiterplates (Nunc, Roskilde, 354 
Denmark) as well as a ranging concentrations of the control, CHX acetate (assay concentrations 50 355 
µM – 1,6 µM). The plates were placed in a Synergy H1 Hybrid Reader (BioTek, Winooski, VT, USA). 356 
Aliquots (90 µL, to give a total assay volume of 100 µL) of the prepared bacteria suspension was 357 
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added to the test wells by an automatic injector with tracking of the luminescence emission every 358 
second for 180 s. Three independent measurements were performed. 359 
3.4.4. Promotor activity based whole-cell biosensor assay 360 
Whole cell mode of action specific biosensors were used to determine if the activity of 1 361 
correlates with some previously known modes of actions. The biosensors were generated by cloning 362 
promoter fusions to luxABCDE in the plasmid pBS3Clux and subsequent recombination into the sacA 363 
site on the B. subtilis chromosome as described [32]. Interference with DNA replication, transcription, 364 
translation and fatty acid synthesis was tested by B. subtilis strains containing luxABCDE fusions to 365 
the promotors of the genes yorB, helD, yheI and fabHB respectively, as described for the firefly 366 
luciferase as reported [36]. Inhibition of cell wall synthesis was tested by a bacitracin inducible 367 
promoter construct described [32] based on the promotor of liaI fused to luxABCDE. The veg promoter 368 
fusion described in the same paper was used as a luminescence control. In addition a panB-luxABCDE 369 
promoter fusion described as a lacZ-fusion in patent US20020164602A1 [39] was used to test for 370 
inhibition of folic acid synthesis (details in Table 3). Compound 1 was tested in a two-fold dilution 371 
series starting with two x B. subtilis MIC (MIC = 6.25 µM). The respective control antibiotics were set 372 
up similar to the tested compound. The experiments were run at room temperature. Otherwise 373 
identical setup to the antimicrobial assay protocol (section 3.3.1) was used with additional 374 
measurement of luminescence every 15 min for 8 h. Peak luminescence of the controls was compared 375 
to luminescence of cells treated with 1. 376 
3.5. Synergistic effects of 1 and 6 377 
The ability of 6 to lower the MIC values of 1 against S. aureus, E. faecalis, E. coli, P. aeruginosa and 378 
S. agalactiae (Gr. B) was tested using the same setup as described in chapter 3.3.1. (Antibacterial assay). 379 
Mixtures of 1 and 6 were prepared using a checkerboard titration setup. Both compounds were 380 
prepared at ranging concentrations resulting in assay concentrations of 50, 25, 12.5, 6.25, 3.13 and 1.56 381 
µM of each compound. The finished plate with the dilution is illustrated in Figure 6. 382 
 383 
 384 
Figure 6. Layout of the mixtures of securamine H (1) and securidine A (6) in the compounds plate 385 
prepared to measure if a mixture of 1 and 6 would result in lower MIC values than 6 alone. The 386 
dilution were diluted 1:1 in the assay plate. . 387 
4. Conclusions 388 
Securamine H (1) was found inhibit the viability of G+ bacteria and to reduce metabolic activity 389 
in B. subtilis. The effect was shown not to be caused by interference with DNA replication, 390 
transcription or translation, nor by interference with fatty acid, cell wall and folic acid synthesis and 391 
could not be explained by disruption of the cell membrane. The mode of action of 1 thus remains to 392 
be deconvoluted. However, as the result indicates that 1 has an intracellular target, the compound 393 
serves as an interesting starting point further investigations. The herein presented results 394 
demonstrate that marine bryozoans can be used as a source of compounds with antibacterial activity.  395 
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